University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Masters Theses

Graduate School

8-2006

Psychosocial Correlates of Methamphetamine Use
Greg Joseph Eisinger
University of Tennessee, Knoxville

Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes
Part of the Social Work Commons

Recommended Citation
Eisinger, Greg Joseph, "Psychosocial Correlates of Methamphetamine Use. " Master's Thesis, University
of Tennessee, 2006.
https://trace.tennessee.edu/utk_gradthes/4464

This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE:
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu.

To the Graduate Council:
I am submitting herewith a thesis written by Greg Joseph Eisinger entitled "Psychosocial
Correlates of Methamphetamine Use." I have examined the final electronic copy of this thesis
for form and content and recommend that it be accepted in partial fulfillment of the
requirements for the degree of Master of Science in Social Work, with a major in Social Work.
David Patterson, Major Professor
We have read this thesis and recommend its acceptance:
John Wodarski, William Nugent
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

To the Graduate Council:
I am submitting herewith a thesis written by Greg Joseph Eisinger entitled "Psychosocial
Correlates ofMethamphetamine Use." I have examined the final paper copy of this thesis
for form and content and recommend that it be accepted in partial fulfillment of the
requirements for the degree ofMaster of Science ·in Social Work, with a major in social
work.

�$\b�
David Patters�
We have read this thesis
and recommend its acceptance:

Accepted for the Council:

Q�'L-

Vice Chancellmand
Dean of Graduate Studies

�6
�

. £55

PSYCHOSOCIAL CORRELATES OF METHAMPHETAMINE USE

A Thesis
Presented for the
Master of Science in Social Work
Degree
The University of Tennessee, Knoxville

Greg Joseph Eisinger
August 2006

ii

Copyright © 2006 by Greg Eisinger
All rights reserved.

iii

DEDICATION

I dedicate this thesis to my parents, Barbara and Eugene Eisinger.
Without the guidance, support, and brilliant example of these two incredible people,
this high level of academic pursuit could never have been possible.
May they live long!

iv

Acknowledgments

I would first like to thank my committee for this thesis, Dr. John Wodarski, Dr.
William Nugent, and Dr. David Patterson, whose cautions, insights, pointers, and
instruction have helped guide a novice researcher through this complex project. The
agencies which have given approval and worked with me on this research also deserve
recognition including the Council for Alcohol and Drug Abuse Services (CADAS;
Chattanooga, TN), Genesis Recovery Center (Lake City, TN), the University of
Tennessee's College of Social Work (Knoxville, TN), the Helen Ross McNabb Center
(Knoxville, TN), Volunteer Ministries (Knoxville, TN), Knox Area Rescue Ministries
(Knoxville, TN), Knox Co. Drug Court (Knoxville, TN), and Cornerstone of Recovery
(Louisville, TN). I would also like to thank personally some of the hard-working
individuals who have given their time and input into the success of this study: Martha
McCallie, John Bailey, Brenda Lawson, Frank Spicuzza, Heather Parris, Dr. Stan Bowie,
Dan Schultz, Ron Hanaver, Jacqueline Berry, Deisha Shah, Melody Jordak and Natalie
Crippen.
Lastly, I would like to acknowledge the participants themselves, for giving their
time, sharing their stories, and working so hard to fight this insidious addiction. Many of
them are walking examples that recovery from this drug IS POSSIBLE and that it is a
myth to say otherwise.

V

Abstract

Methamphetamine (MA) abuse is a devastating problem which has been sweeping
the United States from west to east and has reached epidemic proportion in many areas.
Literature on the drug itself, its history, and effects are reviewed. The current project
aimed to examine the psychosocial correlates of MA use using Hudson's Multi-Problem
Screening Inventory (MPSI).
The MPSI was given to a control group of undergraduate social work students
(n = l7) and a group of past-year MA users (n= l5). All participants supplied demographic
information and completed a questionnaire on their MA-use habits. Differences between
users and non users were examined across the 27 domains of the MPSI, and subscales for
which MA users exceeded the clinical cutting score were noted. In addition, the
correlation between severity of craving for MA and MPSI scores was examined.
MA users differed significantly from non users on the depression, partner, child,
and neighbor problems, aggression, fearfulness, ideas of reference, phobias, guilt,
disturbed thinking, memory loss, and drug abuse subscales. MA users exceeded clinical
cutting scores on all of these scales except child problems, fearfulness, and ideas of
reference, in addition to self-esteem, sexual discord, personal stress, friend, school, and
coworker problems, and confused thinking. Severity of craving was correlated with MPSI
score on all MPSI scales except, self-esteem, sexual discord, mother, father, friend,
coworker, school, and family problems, suicide, non-physical abuse, and alcohol abuse.
Interesting findings regarding the control group are also discussed.
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Preface

The study described in the following pages represents the author's first attempt at
conducting original research. All the studying, practicing, and supervision in the world
cannot truly prepare one for the practical aspects, frustrations, and challenges of
designing and executing a valid empirical study. I am making this preface simply to point
out that the experience of doing this project has taught me something at just about every
single step of the process, things that would likely change the way I do things were I
doing them over. While these "learning experiences" do not necessarily degrade the
validity of the findings, they do account for some of the decisions that were made
regarding the research question, recruitment, methodology, and analysis.
I would also like to point out the limited generalizability of this study. Although
the specific limitations of this study are discussed at more length within the body of this
paper, they should also be mentioned as a something of a disclaimer on what you are
about to read. Some of these problems are: small sample size, unequal demographic
characteristics between groups, regional isolation, poly-substance use by MA users, and
the presence of substance use and clinical psychosocial pathology amongst non users.
Though not completely damning for the validity of this study, these (and other) variables
may have created illusory correlations or caused type II errors. Having stated the
preceding, I would also like to acknowledge that this study does bring valuable,
previously-unresearched information to the field and serves as a foundation for further
research.
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Chapter 1:
Introduction and Background of the Methamphetamine Problem

What is Methamphetamine?
Methamphetamine (MA) is a powerful psychomotor stimulant of the central
nervous system (CNS), the non-medical use of which has reached epidemic proportions
in many areas across the nation (Miller & Kozil, 1991; Cunningham & Thielemier, 1995;
Anglin, Burke, Perrochet, Stamper, & Dawud-Nouris, 2000). The chemical composition
of MA nearly mirrors that of pseudoephedrine, a commonly-used, over-the-counter cold
medicine (Center for Health and Health Care in Schools [CHHCS], 2004). The MA
molecule, in fact, differs from pseudoephedrine and ephedrine by no more than the
absence of a single atom of oxygen (R. Rawson, personal communication, March 20,
2006). As a result, MA can be easily synthesized in a home laboratory using very crude,
commercially available, ingredients (Smith, 1969; Allen & Cantrell, 1989; Heischober &
Derlet, 1989; Irvine & Chin, 1991). Instructions for making MA via a number of different
methods can be obtained readily on the internet and other easily accessible locations
(Murray, 1998). Today's MA commonly contains cocaine (Klatt, Montgomery, Namiki,
& Noguchi, 1986), as well as other potentially hazardous contaminants.
MA can be smoked, swallowed in pill form, snorted, injected, or taken anally
(Gorman, Clark, Nelson, Applegate, Amato, & Scro}, 2003). Intravenous use is
associated with poorer outcomes and greater exposure to infectious disease. In fact,
Rawson, Anglin, and Ling (2002) state, that "unless users begin injecting the drug, it may
be possible for many individuals to take methamphetamine for a period of years before
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intolerable negative consequences of the drug begin to occur" (p. 8). MA must be
rendered a water-soluble powder (MA Hydrochloride [HCl]) if it is to be stable enough to
be used (Derlet & Heischober, 1990). This snortable form of MA contains impurities and
is commonly seen as a white or brown, odorless, crystalline powder known as "crank,"
"speed," or "chalk" (National Institute on Drug Abuse [NIDA], 1996). MA HCl can also
be converted to a liquid form for injection. In order to do so, an oily form of MA known
as "paste" or "base" is simply dissolved in water (National Drug and Alcohol Research
Centre [NDARC], 2006). A more potent, smokable form of MA is also produced from
the powder. According to Derlet & Heischober (1990), "once the methamphetamine HCl
is produced, making ice involves a process analogous to making rock candy out of sugar"
(p. 626). This form of the drug is pure and looks like clear, solid crystals often referred to
as "ice," "crystal," or "glass" (NIDA, 1996). MA is typically smoked in a glass pipe
(NDARC, 2006) or by making a small bowl out of aluminum foil, heating the foil from
beneath with a lighter, and inhaling the smoke through a straw (Derlet & Heischober,
1990). An average dose of ice or the injectable base is .1 grams, sometimes called a
"point" (NDARC, 2006). Users of the low-purity powder (MA HCl) typically use about
.5 grams at a time (NDARC, 2006). A person smoking or injecting MA first experiences
a blast of euphoric pleasure as a result of a large, rapid release of dopamine (Wesson &
Smith, 1978; Gawin & Ellinwood, 1988; Gorman, Clark, Nelson, Applegate, Amato, &
Scrol, 2003; R. Rawson, personal communication, March 20, 2006). According to NIDA
(1996), the user does not experience this initial intense rush when snorting or taking the
drug orally. The desired main effects, which can be achieved exclusively in low doses
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(Nordahl, Salo, & Leamon, 2003), include euphoria, increased wakefulness/alertness,
reduced reaction time, decreased appetite, behavioral disinhibition, increased sexual
desire, and perceived sexual performance (Derlet & Heischober, 1990; NIDA, 1996) as
well as intensified emotions and altered self-esteem (Gawin & Ellinwood, 1988). The
overall syndrome has been described as feeling similar to, and being clinically difficult to
distinguish from, the intoxication produced by cocaine (Seiden, 1991). However, lasting
somewhere between 7 and 17 hours (Cook, 1991), the duration of the high produced by
MA dwarfs that of both powder and rock cocaine (by four, eight, or even ten times;
Heischober & Derlet, 1989; Seiden, 1991) as well as d-amphetamine. This does not seem
to be substantially affected by method of administration (Harris, Boxenbaum, Everhart,
Sequeira, Mendelson, & Jones, 2003), although some report that the high from smoking
and injecting wears off more quickly than snorting or ingesting orally (Derlet &
Heischober, 1990). The effects are also experienced much more quickly when the drug is
smoked or injected (within 5-10 seconds as opposed to 3-5 minutes for snorting and 1520 minutes for ingestion ; Derlet & Heischober, 1990; NIDA, 1996; Office of National
Drug Control Policy [ONDCP], 2003).
People who use MA have cited many different reasons for doing so. These
reasons vary dramatically and include: decreased need for sleep/reduction of fatigue,
improved social competence/confidence, weight-loss, self-medication of psychiatric
symptoms, improved productivity, heightened creativity, peer pressure, and sexual
enhancement (Gorman, Clark, Nelson, Applegate, Amato, & Scrol, 2003). However,
these and other desired effects cited above, quickly transform to their opposites under
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chronic use. The ravages of addiction to MA take an extremely powerful hold over its
victims. As a surprising anecdote, given the disastrous effects of MA (which will be
discussed at length in chapter 2), MA appears to carry less of a stigma on the street than
other similar drugs (Pach & Gorman, 2002). This author speculates that this may be
related to a historical neglect of MA in drug education and prevention campaigns
regarding these consequences.
A BriefHistory ofMA
The first synthesis of amphetamine (AP) occurred in 1887 (Murray, 1998); that of
its derivative, MA, followed in 1919 (CHHCS, 2004). The term "AP's" refers to a class
of stimulants containing amphetamine, dextroamphetamine, and MA. Although MA and
AP are very closely related in terms chemical structure and psychophysical effects, MA
has much more powerful effects on the central nervous system (NIDA, 2005). AP's
entered the licit market in the form of a nasal inhaler prescribed to reduce the congestion
associated with allergic rhinitis (Snyder, 1986; Murray, 1998); use in the treatment of
narcolepsy began in 1935 (Murray, 1998). In the later 1930's, AP's became popular
amongst college students, businesspeople, truck drivers, and athletes for its stimulant
properties (Murray, 1998). During World War II, use of AP's went international as
Canadian, German, and English soldiers found them useful in counteracting fatigue
during combat (Spotts & Spotts, 1980). After the War, MA became extremely common in
the US as well as Japan, Great Britain, and Sweden (Kramer, Fischman, & Littlefield,
1967; lnghe, 1969; Brill & Hirose, 1969). During the SO's and 60's, AP use continued to
increase in the US, to an epidemic level in some areas of California (Smith, 1969). It was
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during the 1960's that intravenous use came on the scene (Murray, 1998). Once the
Controlled Substance Act of 1970 placed restrictions on the various supply chains of AP,
users and dealers sought out a new source of product and found it in MA, which could be
produced more easily (Derlet & Heischober, 1990).
Although illicit synthesis and distribution of MA had been occurring since the
1960's (Murray, 1998), clandestine laboratories began to spring up at an exponential rate
throughout the 80's, particularly on (though not confined to) the west coast and Hawaii
(Irvine & Chin, 1991). Before that time, MA production and distribution had been largely
controlled by large, organized biker gangs like the "Hell's Angels," that created the
substance from its precursor chemicals in remote areas in which the fumes could go
unnoticed (Irvine & Chin, 1991; Drug Enforcement Agency [DEA], 1996; Rawson,
Anglin, & Ling, 2002). Throughout the early 1990's, these groups started to be replaced
by Mexican drug-cartels (DEA, 1996) and small, home-run, clandestine operations as the
primary suppliers of American MA (Rawson, Anglin, & Ling, 2002). According to Pach
and Gorman (2002), today's high-purity MA, produced using the red phosphorous
method, is normally brought into the US by the Mexican-based organized traffickers,
while lower-quality MA typically originates with the small, home-based laboratories and
motorcycle gangs.
Although continually available previously, the illicit use of MA experienced a
dramatic resurgence in the late l 980's and the 1990's (Miller & Kozel, 1991; Community
Epidemiological Work Group, 2000). Certain authors with ears-to-the-ground on the west
coast (Derlet & Heischober, 1990, among many others) were able to predict this trend as
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it was just beginning. Others still saw warnings about the potential spread of MA as
unfounded media and governmental scare-tactics, creating an unnecessary sense of public
hysteria about the drug (Lauderback & Waldorf, 1993; Jenkins, 1994). As the statistics
collected throughout the 1990's reveal, such warnings turned out not to be so
unwarranted.
The number of people trying MA at some point in their lives increased by 150%
in the second half of the 90's alone (Substance Abuse and Mental Health Services
Administration [SAMHSA], 2000). Between 1991 and 1994, national MA-related
emergency room visits jumped 256% (SAMHSA, 1995) according to one estimate, and
350% according to another (Molitor, Truax, Ruiz, & Sun, 1998). Admissions to treatment
centers for MA-related reasons also increased drastically (Cannon, 1996), more than
double, in fact, between 1992 and 1997 alone (SAMHSA, 1999). Between 1994 and
2000, seizure of clandestine laboratories in the US increased by 594% (DEA, 2001).
As the DEA (2006) and others (e.g. Fox, Kass, & Christeson, 2006) point out, the
spread of the MA epidemic during the 1990's began on the west coast, and has quickly
flowed eastward to encompass nearly the entire US. The one region which has yet to be
overtaken by MA is the east coast, particularly northeast (SAMHSA, 2003; DEA, 2006).
A Public Broadcasting Service (PBS) documentary entitled The Meth Epidemic
explores the history, present state, and future of the national MA epidemic (2005). In this
film, the authors emphasize a trend in MA use during the 1990's. Although a steady
increase is the overall pattern in the 1990's, it was shown that there were sharp decreases
1996 and 1999. Specifically, it was found that demand for MA (and the problems
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associated with its use) covaries nearly perfectly with the average purity of the substance.
In an interview, one of the researchers (PBS, 2006), Steve Suo, speculates on several
explanations for this trend. First, when a drug is purer, its effects become more desirable.
Conversely, when purity is low, people are less likely to become addicted to it. Finally,
Suo states that market mechanisms similar to those of other commodities are at work. If
someone is paying the same price for a gram of MA, they are likely to buy more when
the effects are stronger and last longer. It is as if they are paying less for the same
"amount" of high. According to Puder, Kagan, and Morgan (1988), street had MA
become almost completely pure during the late 1980's. According to SAMHSA (2003),
however, average purity decreased from 72% to 40% between 1994 and 2001.
Several governmental efforts have attempted to capitalize on this effect and
control the supply and purity of MA by limiting access to precursor chemicals.
Cunningham and Liu (2003) examined the impact of several of these large-scale
legislative interventions targeting the MA problem on reducing MA-related hospital
admissions. The first governmental initiative described was the Chemical Diversion and
Trafficking Act of 1989. This law regulated the bulk, powder form of MA precursors
pseudoephedrine and ephedrine. Following the passage of this act, MA-related hospital
visits took a sharp decline which lasted for about two years (Cunningham & Liu, 2003).
In 1995, the Domestic Chemical Diversion and Control Act continued this cause by
regulating products in which ephedrine was the sole active ingredient. The steep drop in
MA-users needing emergency medical care which followed lasted about six months
(Cunningham & Liu, 2003). The Comprehensive Methamphetamine Control Act of 1997
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took it one step further by regulating any product containing pseudoephedrine, regardless
of the presence of other active ingredients and achieved a decline in emergency room
admissions which lasted for about one year (Cunningham & Liu, 2003).
The Current National Impact of the Methamphetamine Epidemic
MA has been described by many as the worst drug problem in America currently
(Jefferson, 2005; Fox, Kass, & Christeson, 2006; DEA, 2006). In 2003, there were more
than twice as many amphetamine (including MA) users as cocaine users and more than
three times as many as heroin users worldwide (United Nations Office on Drug and
Crime, 2003). Rawson, Anglin, and Ling (2002) report that MA use worldwide is
exceeded only by that of marijuana. SAMHSA (2005) reported a national past-year-use
prevalence among persons age 12 and older of .6% in 2004. Having begun on the west
coast and gradually spread eastward, many of the areas on and near the Pacific coast have
been hit the hardest by the ravages of MA. Some areas of California, for example, had
more admissions to treatment in 2001 for MA than for alcohol (Gorman, Clark, Nelson,
Applegate, Amato, & Scro1, 2003; California Department of Alcohol and Drug Programs,
2001). In some western states, such as Oregon, MA has also become the leading cause of
property crime as well as the leading reason for children being removed from their homes
(PBS, 2006). According to the ONDCP (2002), MA "accounts for 33 percent of domestic
violence among drug sellers" as well as "substantial percentages of nonviolent crime (20
percent), violent crime (16%), prostitution (15 percent), and gang-related crimes (12
percent) among sellers" (p. 1). Despite the continued pervasiveness of MA use nationally,
no increase in use was noted between 2002 and 2004 (SAMHSA, 2005). Encouragingly,
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the number of clandestine labs seized actually decreased between 1999 and 2004 (NIDA,
2005).

Meth and HIV.
A vast amount of research has addressed the influence of MA on the spread of
HIV and other infectious diseases (Frosch, Shoptaw, Huber, Rawson, & Ling, 1996;
Anderson & Flynn, 1997; Gorman, Barr, Hansen, Robertson, & Green, 1997; Centers for
Disease Control [CDC] 1998; Needle, Coyle, Cesari, Trotter, Clatts, Koester, Price,
McLellan, Finlinson, Bluthenthal, Pierce, Johnson, Jones, & Williams, 1998; Gorman &
Carroll, 2000; Gorman, Clark, Nelson, Applegate, Amato, & Scrol, 2003). Although
transmission of pathogens is a concern with any intravenously administered drug, it is
especially rampant with MA use. One study of individuals entering a substance abuse
treatment facility found MA injectors three times more likely than injectors of other
drugs to test positive for HIV (Harris, Thiede, McGough, & Gordon, 1993). No more
recent information on this phenomenon was uncovered. However, this disparity is likely
to persist due to the interplay of risk factors already commonly associated with
intravenous drug such as sharing of dirty needles, and the increase in sexual desire (Klee,
1993), number of partners (Zule & Desmond, 1999), and sexual risk-taking behaviors
(such as increased vaginal/anal intercourse and decreased condom use) commonly
reported by MA users (Frosch, Shoptaw, Huber, Rawson, & Ling, 1996; Molitor, Ruiz,
Flynn, Mikanda, Sun, & Anderson, 1999). The drug's status as a "sex-drug" among urban
"men who have sex with men" (MSM), also plays a role (Mattison, Ross, Wolfson, &
Franklin, 2001; Mansergh, Colfax, Marks, Rader, Guzman, & Buchbinder, 2001;
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Gorman, Clark, Nelson, Applegate, Amato, & Scrol, 2003). The relationship between
MA and HIV will be mentioned again in Chapter 3.

Prescribed use.
MA continues to be prescribed for the treatment of narcolepsy (Mitler,
Hajdukovic, & Erman, 1993), obesity (King & Ellingwood, 1992), and ADHD (Kroutil,
Van Brunt, Herman-Stahl, Heller, Bray, & Penne, in press). This practice, the extent of
which is largely unknown, is quite controversial due to the high potential for
redistribution, misuse, and addiction. However, as Kroutil, Van Brunt, Herman-Stahl,
Heller, Bray, & Penne (in press) point out, the majority of misuse of prescribed stimulant
medications involves drugs other than MA. This may be related to the relatively limited
availability of prescription MA as compared with that of other drugs such as
methylphenidate and dextroamphetamine.

Treatment.
It is also important to briefly discuss the treatment and prognosis of MA
dependence. It has been a myth amongst the public, as well as certain researchers and
treatment professionals, that full recovery from MA addiction is simply not possible.
However, any investigation into the research on the subject quickly dispels this notion.
Several studies comparing treatment outcomes for cocaine dependence versus MA, for
example, found no major differences between the two groups (Huber, Ling, Shoptaw,
Gulati, Brethren, and Rawson, 1997; Rawson, Huber, Brethen, Obert, Gulati, Shoptaw, &
Ling, 2000). While the unique physiological mechanisms by which MA addiction takes
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its firm hold on the body create special challenges for recovery, they do not render it
impossible.
Although an in-depth discussion of the specific treatments available for MA
dependence is outside of the scope of this paper, several treatment models which have
been associated with positive outcomes, will be mentioned briefly. The most well-known
intervention is called the MATRIX model and is well-supported by empirical research
(Shoptaw, Rawson, McCann, & Obert, 1 994). According to Huber, Ling, Shoptaw,
Gulati, Brethren, & Rawson ( 1 997), the MA TRIX model "is designed to integrate several
disparate interventions into a comprehensive, structured approach. Elements of the
treatment include individual therapy, relapse prevention and family education groups,
urine testing, and 1 2-step program involvement" (p. 44). The treatment manual for this
program is available (see Rawson, Obert, McCann, Smith, & Scheffey, 1 989).
As of yet, the pharmacological treatment of MA dependence is largely confined to
the symptoms of depression and psychosis induced by neurochemical/structrual damage,
and the medical symptoms of overdose and acute withdrawal (R. Rawson, personal
communication, March 20, 2006). Tri-cyclic antidepressants are commonly used to
address the former (Wesson & Smith, 1 978). One trial of the tri-cyclic antidepressant
imipramine with 32 MA-dependent individuals, however, produced no significant
changes in Beck Depression Inventory score, stimulant craving, self-report of time since
last use of stimulants, or percentage of urinalyses positive for [the drug]" (Galloway,
Newmeyer, Knapp, Stalcup, & Smith, 1 994). However, antipsychotic medications such
as chlorpromazine and haloperidol are helpful with the some of the symptoms of
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withdrawal (Bell, 1973; Espelin & Done, 1968; Snyder, 1973). In regard to the
physiological symptoms, Derlet & Heischober (1990) report that there has been some
success in using phentolamine and nitroprusside to address MA-induced hypertensive
crisis, and haloperidol to stabilize blood pressure.

Impact on children.
Unfortunately, given the frequency with which children are found by law
enforcement living at MA labs, very little is known about the long-term consequences of
inhaling MA vapors on children's health and development (CHHCS, 2004). Dixon &
Bejar (1989) found that children whose mothers use stimulants during pregnancy are at
heightened risk for brain injury, even in full-term births.
Johnson (2005) does an excellent job of describing the impact of this drug on
children whose parents are users in his book entitled Meth: The Home-Cooked Menace.
He states that "for children living with parents on meth, going hungry is just part of the
bargain. Meth users don't eat because they don't get hungry, so they often forget that
their kids needs" (p. 56). Johnson also points out that hallucinations, delusions, and
increased libido often result in severe physical and sexual abuse of children. In addition,
many children who are exposed to MA fumes in their homes actually test positive for the
substance, triggering many of the same effects experienced by the users themselves
(Johnson, 2005). Though largely unknown, the long-term effects of exposure to the
fumes created by cooking MA are likely to be quite detrimental for development and
health. Of course, these types of problems are mentioned because of the severe harm and
trauma which they create for children. However, less devastating effects, such as lack of
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structure, discipline, hygiene, affection, and distorted social learning, are equally notable
and occur extremely frequently in the homes of MA users. Johnson (2005) describes one
family in which two children, a two-year old and a four-year old, were found who had
never learned to drink from a cup, use the toilet, or speak normally, and had rotted-out
teeth.

Environmental impact.
A major concern regarding the current state of MA production is its deleterious
effects on the environment in which it is cooked. According to Irvine and Chin (1991),
"the chemicals used in the manufacturing process can be corrosive, explosive, flammable,
toxic, and possibly, radioactive" (p. 36). These authors also point out that, due to the
amateur status of MA cooks, they often use improper proportions of various ingredients,
resulting in the creation of extremely toxic byproducts, which are typically not disposed
of in an environmentally safe manner. The introduction of these chemicals, and other
ingredients, to the air, ground, and the water table can produce hazardous conditions for
residents of an entire community. The effects of MA production also have more localized
effects. As several authors point out, once MA has been cooked in a house, it is difficult
to ever get the smell completely out (Johnson, 2005). In addition, these lingering vapors
themselves may be strong enough to be deadly for those who inhale them (Irvine & Chin,
1991).

Current governmental interventions.
Although federal response to the epidemic of MA use has been criticized as slow
(Rawson, Anglin, & Ling, 2002), notable legislative progress has been made. As
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mentioned, the passage of several laws (including the Controlled Substance Act of 1 970,
the Chemical Diversion and Trafficking Act of 1 989, the Domestic Chemical Diversion
and Trafficking Act of 1 995, and the Comprehensive Methamphetamine Control Act of
1 997) have been successful in producing significant, though short-lived, decreases in MA
use. The Food and Drug Administration (Rados, 2004) has also recently helped to limit
precursor access by banning the sale of any dietary supplement containing ephedrine.
This policy, however, was precipitated by the adverse health effects of ephedrine, rather
than its contribution to clandestine MA production, and data on its impact on MA
availability is not available. The DEA (2006) reports that although federal initiatives have
been successful in reducing the number of home-run clandestine laboratories by
controlling precursors, it is not expected that this will greatly affect national MA use.
This is because the Mexican cartels, which now control the majority of importation of
MA, have the ability to increase production to a degree which offsets US government
efforts. However, stiff legal penalties are also in place as deterrents for potential users.
According to US representative Judy Biggert (HR4553: The Club Drug Antiproliferation
Act, 2000), the current sentencing guidelines for possession of one gram of MA are
equivalent to those for two kilograms of marijuana, substantially more severe than that of
ecstasy and other drugs.
Included in the wording of the latest revision of the USA PA TRIOT Act expected
to be signed into law in 2006, the Combat Methamphetamine Epidemic Elimination Act
will be "the most important meth bill that's ever been passed by the United States
Congress" (Suo & Barnett, 2006, p. 1 ). Beginning on September 30, 2006, all products
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containing pseudoephedrine must be kept behind the counter with buyers having to show
identification in order to purchase them. Consumers will also be limited to purchasing
1 20 pills in a day and 300 pills in a month. This act goes one step further to combat mass
production of MA in other countries by enforcing economic sanctions against nations
which allow importation of precursor chemicals beyond "legitimate demand" (Suo &
Barnett, 2006).
Currently awaiting its day to be heard before the full House of Representatives,
the Methamphetamine Epidemic Elimination Act (MEEA; 2005) seeks to "further
regulate and punish illicit conduct relating to methamphetamine" (p. l ). The provisions of
this bill seek to impose stricter regulations and penalties on the domestic and
international distribution of MA precursor chemicals (pseudoephedrine, ephedrine,
phenylpropanolamine), toughen punishments for MA production and trafficking, increase
monitoring of environmental effects of MA production, and provide grants to drug court
programs, MA availability reduction initiatives in "hot spot" areas, and programs that
help drug-endangered children.
As Rawson, Anglin, & Ling (2002) point out, regulation of the supply of
precursor chemicals cannot be the only counterattack against this modern menace;
complete elimination of the supply of chemicals like pseudoephedrine is simply not
feasible due to their licit utility. It is also starkly stated in the above article that, "at
present, there are few signs to suggest that the methamphetamine epidemic of the l 990's
will simply become an unpleasant memory, as did the PCP epidemic of the l 970's" (p. 8).
As Reuter and Caulkins (2003) point out, governmental effort now needs to focus on the
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durability of the impact following legislative intervention. The authors point out the
limited utility of MA-related emergency room admissions alone as an indicator of MA
use. They also state that other indicators give ambiguous results as to whether the
governmental initiatives are having an effect at all. For example, "precursor control is a
supply-side intervention that should drive up prices. As it becomes more difficult to
find precursors, production costs rise until suppliers develop new sources (perhaps in
other countries) or new technologies. Higher prices should lead to fewer persons using
and/or lower quantities consumed per user" (Reuter & Caulkins, 2003, p. 1 1 7 7).
Price of MA, however, has been falling somewhat continually for the past 20 years
(ONDCP, 2004). One further card in the hand of MA, is that it typically much less
expensive than other similar drugs (Pach & Gorman, 2002), costing as little as 2 5 % as
much as cocaine (Rawson, Anglin, & Ling, 2002). As of 200 3 , one gram oflow-grade
MA could be bought on average for as little $ 5 0 (ONDCP, 2004).
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Chapter 2:
A Review of the Known Correlates and Consequences of MA Use

Neurochemical
The devastating impact of MA use begins with its toxic effects on the body.
Perhaps most destructive, is the way in which MA manipulates neurochemical
characteristics of the human brain. The immediate effect of MA is a large release of
dopamine (R. Rawson, personal communication, March 20, 2006) creating a consequent
rush of pleasure, which has been described as sexual in nature (Gorman, Clark, Nelson,
Applegate, Amato, & Scro], 2003). This release represents six times that created by
nicotine, three times that of cocaine (R. Rawson, personal communication, March 20,
2006), and as much as ten times that of an orgasm (Associated Press, 2004). MA also,
however, essentially "clogs" dopamine reuptake pumps, causing a long-lasting depletion
of dopamine in the vesicle (Wagner, Seiden, & Schuster, 1979; Wagner, Ricaurte,
Seiden, Schuster, Miller, & Westly, 1980). Males may be more susceptible to this MA
induced depletion of dopamine than females (Wagner, Tekirian, & Cheo, 1993).
As a result of the blocked reuptake, dopamine begins to accumulate in the
synapse. Dr. Richard Rawson states (personal communication, March 20, 2006) that
while cocaine is known to produce a similar inhibitory effect on dopamine reuptake, MA
goes even further by crossing the pre-synaptic cell wall to drive dopamine out into the
synapse. This results in spontaneous firing and over-stimulation of the postsynaptic
neuron and the creation of free radicals which damage the nerve terminals themselves
(Scheel-Krueger, 1972; Pitts & Marwah, 1988). Dopaminergic neurotoxicity is the term
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for the damage to dopamine receptors and terminal buttons that results from this buildup
of cytoplasmic pools of dopamine in the synapse (Ricaurte, Guillery, Seiden, Schuster, &
Moore, 1982; Wagner & Walsh, 1991).This condition has been associated MA use in
both humans and rats in numerous studies (e.g. Kogan, Nichols, & Gibb, 1976; Fuller &
Hemrick-Luecke, 1980; Ricaurte, Guillery, Seiden, Schuster, & Moore, 1982; Gibb,
Johnson, & Hanson, 1990; Robinson, Yew, Paulson, & Camp, 1990; ltzhak, Gandia,
Huang, & Ali, 1996).
MA impacts not only dopaminergic neuropathways, but nearly every
neurotransmitter in the brain (Nordahl, Salo, & Leamon, 2003). MA also decreases the
activity of tyrosine hydroxylase (an enzyme which inhibits the metabolism of
catecholamines) and reduces the number of dopamine transporter pumps (Kogan,
Nichols, & Gibb, 1976; Itzhak, Gandia, Huang, & Ali, 1996; McCann, Wong, Yokoi,
Villemagne, Dannals, & Ricaurte, 1998). This loss of dopamine transporter pumps is
associated with psychomotor impairment producing symptoms similar to those of
Parkinson's Disease (Volkow, Chang, Wang, Fowler, Leonido-Yee, Franceschi, Sedler,
Gatley, Hitzemann, Ding, Logan, Wong, & Miller, 2001) as well as a high likelihood of
experiencing residual psychiatric symptoms such as psychosis (Sekine, Iyo, Ouchi,
Matsunaga, Tsukada, Okada, Yoshikawa, Futatsubashi, Takei, & Mori, 2001). Sekine,
Iyo, Ouchi, Matsunaga, Tsukada, Okada, Yoshikawa, Futatsubashi, Takei, and Mori
(2001) found that this depletion of dopamine transporters, and consequent induction of
psychiatric and psychomotor symptoms, may be persist long after cessation of use,
especially when the duration of use was longer.
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MA also has deleterious effects on areas o f the brain other than those innervated
by dopamine, such as the cortex (Eisch & Marshall, 1 998; Deng, Ladenheim, Tsao, &
Cadet, 1 999; Stumm, Schlegel, Schafer, Wurz, Mennel, Krieg, & Vedder, 1 999; Volkaw,
Change, Wang, Fowler, Franceschi, Sedler, Gatley, Hitzemann, Ding, Wong, & Logan,
200 1 ). The density of serotonin transporter molecules is reduced by repeated
administration of MA, resulting in elevated aggression which may persist long after
cessation of use (Sekine, Ouchi, Takei, Yoshikawa, Nakamura, Futatsubashi, Okada,
Minabe, Suzuki, Iwata, Tsuchiya, Tsukada, Iyo, & Mori, 2006). Noradrenergic reuptake
is also inhibited in the by the use of MA (Murray, 1 998), with effects on cognition.
At a lecture entitled The Nature ofthe National Methamphetamine Epidemic
(March 20, 2006), Dr. Richard Rawson described the pscyho-affective implications of the
catecholamine depletion and nerve terminal damage for the brain' s natural reward
system. He states that a chronic MA user quickly begins to experience a diminished
ability to feel pleasure and to be intrinsically reinforced by anything other than the release
of dopamine achieved upon getting high. Journalist Dirk Johnson (2005) reports in his
book Meth: The Home Cooked Menace that MA cravings are so powerful that users
experience a Pavlovian effect in which the very thought of using causes a small dopamine
release. He ( and others; e.g. R. Rawson, personal communication, March 20, 2006) also
points out that, after periods of 6- 1 2 months or more of abstinence, many recovering MA
addicts will regain these important neurochemical functions. Some research on rhesus
monkeys, however, has found that the effects of MA-induced neurotoxicity can persist
for as much as four years or more of abstinence as measured by decreased concentrations,
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and reuptake, of dopamine and serotonin in several brain regions (Woolverton, Ricaurte,
Forno, & Seiden, 1989).

Neuro-Structural
Thompson, Hayashi, Simon, Geaga, Hong, Sui, Lee, Toga, Ling, and London
(2004) charted the structural brain damage associated with MA use using magnetic
resonance imaging (MRI). They found a significant loss of gray matter (the part of the
CNS containing neurons) in several areas of the limbic system (responsible for emotional
responding), as well as excessive thickening and expanding of white-matter cells, in MA
users. A reduction in hippocampal volume was also observed and correlated with
impaired performance on a memory-recall task. The authors note the reversibility of these
injuries is, as of yet, unknown.

Physical
The use of MA is also associated with numerous disturbing effects on the exterior
of the body itself. One of the most tell-tale signs of a MA user is their teeth. Often termed
"meth-mouth," the teeth of MA users become "blackened, stained, rotting, crumbling, or
falling apart" (American Dental Association [ADA], 2005, p. 1) for a number of reasons.
According to the ADA (2005), the drug itself is acidic, causing wear on the tooth enamel.
The ADA also cites reduction of saliva, increased consumption of carbonated drinks,
increased tendency to grind teeth, and extended periods of neglect of oral hygiene as
factors in the "meth-mouth" syndrome.
In addition to dental consequences, MA use also frequently leads to the
development of skin lesions created by compulsive picking at the skin caused by
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delusional parasitosis, needle marks, and bums suffered during cooking the drug
(Lineberry & Bostwick, 2006). The term "meth bugs" refers to a tactile hallucination of
small insects crawling on and under the skin. MA users often scratch and pick at these
"bugs" to the point of developing deep, open sores. So-called "track" marks are the
"visible scarring of skin along surface vein areas due to repeated injection" and are
associated with the use of any injection drug. This type of lesion has even been used as
criteria for ensuring that all participants in a study are in fact injection drug users
(Bluthenthal, Kral, Gee, Erringer, & Edlin, 2000). Finally, the production of MA in
home-based clandestine labs uses flammable and explosive chemicals, the improper
mixing of which can lead to violent chemical reactions (Hart, McChesney, Grief, &
Schultz, 1 972). For this reason, MA cooks are frequently treated in emergency rooms
with severe bums which require immediate medical intervention (Lineberry & Bostwick,
2006). The volatile environments created by MA labs are a danger to, not only the cooks
themselves, but their children, family members, and law enforcement officers.
Medical

MA use is associated with numerous harmful effects to the various systems of the
body. Tachyphylaxis (rapid development of tolerance) is extremely common with MA
(Smith, 1 969) and long-time chronic users have been known to use as much as 5 - 1 5
grams per day. However, overdoses have been produced at dosages as low as 1 .5 mg
(Zalis & Parmly, 1 963); this is likely an unusual case. Symptoms of overdose include
agitation, anxiety, hallucinations, delerium, and seizures (Derlet & Heischober, 1 990), as
well as disorientation, hyperthermia, photophobia, orthostasis, and ataxia (Buffum &
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Shulgin, 2001). Death via several different bio-mechanisms can occur (Kramer,
Fischman, & Littlefield, 1967; Zalis, Lundberg, & Knutson, 1967; Conci, D'Angelo,
Tampieri, & Vecchi, 1988). MA has been associated in a number of cases with stroke
(Perez, Arsura, & Strategos, 1999; Wang, Hayashi, Chang, Chiang, Tsao, Su, Borlongan,
& Lin, 2001). According to Perez, Arsura, & Strategos (1999), this condition is caused by
either drug-induced exacerbation of preexisting hypertension leading to blood vessel
rupture, or vasoconstriction resulting in arterial obstruction; cerebrovascular hemorrhage
has also been attributed MA (Chyun, 1975; Salanova & Taubner, 1984 ).
Greenwell and Brecht (2003) conducted a highly controlled, retrospective study
of self-reported general health status among MA users between 18-52 years old. It was
found that the presence of a health condition is predicted, as would be expected, by age as
well as prolonged MA use. Other research, however, has found that MA users are no
more likely than users of other drugs to experience adverse health consequences (Anglin,
Kalechstein, Maglione, Annon, & Fiorentine, 1998). Menstrual irregularities and
reproductive difficulties have been associated with MA use in women (Pach & Gorman,
2002).
Continued MA use puts a strain upon the cardiovascular and respiratory systems.
Some common symptoms include tachycardia, hypertension, vasoconstriction, cardiac
dysrhythmia (Leschner, 2000), chest pain (NIDA, 1996), palpitations, and dyspnea
(Derlet & Heischober, 1990). Pulmonary edema and reduction of lung capacity have also
been associated with MA use, especially when the drug is smoked (Hong, Matguyama, &
Nur, 1991). Less common side-effects include hyperthermia, convulsions (NIDA, 1996;
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Hoffman, & Lefkowitz, 1993), rhabdomyolysis (breakdown of skeletal muscle and its
consequent contamination of the blood stream; may lead to renal failure; Chan, Chen,
Lee, & Deng, 1994; Lan, Lin, Yu, Lin, & Chu, 1998), choreoathetosis (an involuntary tic;
Rhee, Albertson, & Douglas, 1988), and myocardial infarction (Hong, Matsuyama, &
Nur, 1991).
Acute withdrawal symptoms last for several weeks and include severe craving,
anhedonia, anergia, and dysphoria (Watson, Hartman, & Schildkraut, 1972; Gawin,
Byck, & Kleber, 1986; King & Ellinwood, 1992; Hyman, 1996). Many of these
symptoms however, persist for much longer (about 6-12 months) after abstinence from
use (R. Rawson, personal communication, March 20, 2006).
As mentioned, MA use is a risk factor for HIV contraction (Baberg, Nelesen, and
Dimsdale, 1996; Peck, Shoptaw, Rotherman-Fuller, Reback, & Bierman, 2005). MA users
who are also MSM are at markedly higher risk for contracting HIV (Chesney, Barrett, &
Stall, 1998; Molitor, Truax, Ruiz, & Sun, 1998; Weber, Chan, George, Hogg, Remis,
Martindale, Otis, Miller, Vincelette, Craib, Masse, Schechter, LeClerc, Lavoie, Turmel,
Parent, & Alary, 2001); this risk is even further exacerbated when the primary route of
administration is injection, due to unsafe injection practices (Molitor, Ruiz, Mikanda, &
Sun, 1996; Bluthenthal, Kral, Gee, Lorvick, Moore, Seal, & Edlin, 2001; Pach and
Gorman, 2002). This problem, however, affects not only MSM, but increasingly so,
heterosexual males (Molitor, Ruiz, Mikanda, & Sun, 1996) and women as well (CDC,
1999). The increased tendency to engage in risky behaviors when under the influence of
MA also contributes to transmission (Frosch, Shoptaw, Huber, Rawson, & Ling, 1996).
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MA has been correlated with an increased rate of selling sex for money or drugs (Molitor,
Ruiz, Mikanda, & Sun, 1996). HIV-infected MA users are also at increased risk
contracting other sexually transmitted diseases such as genital warts, gonorrhea, syphilis,
and Hepatitis B and C (Shoptaw, Reback, & Freese, 2002; Peck, Shoptaw, Rotherman
Fuller, Reback, & Bierman, 2005) as a result of risky behaviors.

Psychiatric
Users of AP's have been found to be more likely to have a history, as well as a
family history, of a psychiatric disorder than non users (Baberg, Nelesen, and
Dimsdale,1996). Chronic use of MA is correlated with depression (Kalechstein, Newton,
Longshore, Anglin, van Gorp, & Gawin, 2000; Peck, Shoptaw, Rotherman-Fuller,
Reback, & Bierman, 2005), increased impulsivity (Richards, Sabol, & de Wit, 1999),
anxiety and hypervigilance (Sekine, Iyo, Ouchi, Matsunaga, Tsukada, Okada,
Yoshikawa, Futatsubashi, Takei, & Mori, 200 I ), stereotypy and compulsivity (King &
Ellinwood, 1992; Murray, 1998), and very often induces long-lasting psychosis including
paranoid ideation, delusions (Ellinwood, 1969; Sekine, Iyo, Ouchi, Matsunaga, Tsukada,
Okada, Yoshikawa, Futatsubashi, Takei, & Mori, 200 I ), and formication (tactile
hallucinations of bugs on/under skin; NIDA, 1996; Peck, Shoptaw, Rotherman-Fuller,
Reback, & Bierman, 2005). Suicidal and homicidal ideation are also common (NIDA,
1 996; Kalechstein, Newton, Longshore, Anglin, van Gorp, & Gawin, 2000). Many
researchers have noted that the symptoms of full blown cases of MA psychosis are
clinically indistinguishable from those of schizophrenia (Bell, 1965; Smith, 1969;
Snyder, 1973; Sekine, Iyo, Ouchi, Matsunaga, Tsukada, Okada, Yoshikawa,
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Futatsubashi, Takei, & Mori, 200 1 ; Nordahl, Salo, & Leamon, 2003). As chronic MA
psychosis can lead to the onset of paranoid schizophrenia, some authors have even
questioned where to draw the line in the fuzzy boundary between the two conditions
(Flaum & Schultz, 1 996). Bell ( 1 973) was able to induce these symptoms using MA in 14
AP-dependent psychiatric patients. These symptoms persist for 1 -2 days on average
(Bell, 1 973), but may remain for much longer in some users (Nordahl, Salo, & Leamon,
2003). MA psychosis can be spontaneously reproduced by a relapse after a long period of
abstinence from use (Sato, Chen, Akiyama, & Otsuki, 1983). Sato, Numachi, and
Hamamura ( 1 992) describe three types of clinical outcomes for MA psychosis after
termination of use: transient, prolonged, and persistent. Commonly described as
"tweaking," Lineberry and Bostwick (2006) describe the syndrome of a MA user coming
off of the drug as, "a dangerous combination of restless anxiety, irritability, fatigue, and
dysphoria." In order to avoid these symptoms, users commonly seek out more of the
drug. In combination with the decreased need for sleep associated with MA use, this
pattern has been known to keep users awake for as many as 3-6 days or more, usually
using the drug every couple of hours (Murray, 1 998).
Griffith, Cavanaugh, and Oates ( 1 969) induced psychosis in four healthy males by
administering 1 0 mg of AP intravenously every hour. Murray ( 1 998) does an excellent
job of summarizing the fascinating progression of the psychosis observed in that study:
Clear-cut psychosis appeared within 1 20 hours of drug administration; for two of
the four participants, symptoms were clear within 24 hours of drug
administration. The first reaction was euphoria. After 50 mg, depression appeared,
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followed by hypochondriacal symptoms and an aversion to food that was so great
that they had to be pushed to eat. None of the participants slept during the first 24
hours. All were lucid and in good contact with reality. About eight hours before
development of unequivocal psychotic symptoms, they became taciturn and
would not discuss their feelings or thoughts. They asked guarded questions about
the room and noises. Onset of florid psychiatric symptoms, paranoid ideation, and
hallucinations was usually abrupt. (p. 231)
In a 2005 study, Peck, Shoptaw, Rotherman-Fuller, Reback, and Bierman
examined the medical, behavioral, and psychiatric correlates of MA dependence in 155
MSM, 98 of which were HIV positive, 57 of which were not. The profile of current
psychiatric comorbidity for the sample (as evaluated using the Structured Clinical
Interview for DSM-IV; Spitzer, William, Gibbon, & First, 1995), was as follows: 31%
had some non substance-use-related Axis I diagnosis; 28.4% had some mood disorder;
20% currently met criteria for a substance-induced disorder other than abuse or
dependence; 1 8.7% had some anxiety disorder; 1 4.9% met criteria for antisocial
personality disorder; and 2.6% had bipolar I disorder. Bristol (2000) found that abuse of
AP's is correlated with development of social phobia.
A number of studies have shown detrimental effects on cognitive performance
following sustained use. Rogers, Everitt, Baldacchino, Blackshaw, Swainson, Wynne,
Baker, Hunter, Carthy, Booker, London, Deakin, Sahakian, and Robbins (1999)
discovered that chronic users of AP's demonstrate delayed and impaired decision making
abilities similar to those seen in patients with damage to the orbital prefrontal cortex.
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Several studies have found that MA-dependent individuals exhibited reduced cognitive
inhibition, creating distractibility and impaired attentional processing and auditory
discrimination (Iwanami, Kanamori, Suga, Kaneko, & Kamijima, 1 995; Salo, Nordahl,
Possin, Leamon, Gibson, Galloway, Flynn, Henik, Pfefferbaum, & Sullivan, 2002).
Simon, Dornier, Carnell, Brethen, Rawson, & Ling (2000) examined cognitive
impairment in current MA users and found significant deficits on several tasks including
recall, digit symbol, Stroop color words, and Trail Making B. These authors also,
however, discovered normative performance on recognition tasks, Trail Making A,
Wisconsin Card Sort, backward digit span, and the FAS test of verbal fluency. Additional
cognitive deficits associated w/ MA use include impaired learning capabilities,
psychomotor speed, and information processing ability (Meredith, Jaffe, Ang-Lee, &
Saxon, 2005). Other research indicates that MA use may decrease the user's sensitivity to
reinforcement delay and amount (Pitts & Febbo, 2004). This effect may relate to the
damage to the brain's natural reward system cited earlier and helps to account for the
difficulties experienced by MA users during recovery. Impairment in memory has also
been correlated with MA use (Thompson, Hayashi, Simon, Geaga, Hong, Sui, Lee, Toga,
Ling, and London, 2004), especially as users become abstinent (Kalechstein, Newton,
and Green, 2003). Mewaldt and Ghoneim (1979), on the other hand, demonstrated that
acute administration of MA can actually improve memory performance on certain tasks.
Demographic
Murray ( 1 998) states that a typical MA user is a "white, lower middle-income,
high-school educated young adult, between 20 and 35 years of age" (p. 23 3). Baberg,
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Nelesen, and Dimsdale (1996) sought to describe the demographic characteristics of the
typical AP user and also found that most were young, white, male, unmarried, uninsured,
and unemployed individuals. In contrast to many other drugs, however, MA users appear
to be more equally male and female (Rawson, Huber, Brethren, Obert, Gulati, Shoptaw,
& Ling, 2000). Huber, Ling, Shoptaw, Gulati, Brethren, and Rawson (1997) looked at the
demographic characteristics of 500 MA users (47.7% daily users) and found a 60-40 ratio
of males to females, a significantly less dramatic split than the 69% male cocaine-using
group (n = 224) in the same study. Gorman, Clark, Nelson, Applegate, Amato, and Scrol
(2003) speculate that the issues leading to and resulting from MA use for women may
differ substantially for those of men.
In the Huber, Ling, Shoptaw, Gulati, Brethren, and Rawson (1997) study, 80.5%
of the 500 MA users were caucasian, compared to only 16. 7 % Hispanic, and 1.9%
African American. Pach and Gorman (2002) found a less dramatic concentration of white
users (67%; n = 1016) and indicate that use among black and Hispanic individuals is
increasing. Rawson, Anglin, and Ling (2002) note that MA use among Asian populations
is also on the rise. SAMHSA's (2005) National Survey on Drug Use and Health,
however, indicate that MA use is most prevalent among native Hawaiian/Pacific
Islanders, persons of two or more races, and American Indian/Alaskan natives. In fact,
MA use by whites was less than one-third as prevalent as use among the
Hawaiian/Pacific Islander group. Of course, the ethnic composition of the region being
examined impacts the distribution of races observed among MA users.
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Of the MA users in Huber, Ling, Shoptaw, Gulati, Brethren, and Rawson's (1997)
study 25.8% were currently married, 25.3% had been previously married, and 48.9% had
never been married. In regard to employment, the largest portion of the sample (61.6%)
was not currently working, as compared with 27 .5% full-time employees, and 10.8%
part-timers, 1997). David Jefferson, author of the Newsweek magazine cover story on
MA entitled A merica 's Most Dangerous Drug states, "the highly addictive stimulant is
hooking more and more people across the socioeconomic spectrum: soccer moms in
Illinois, computer geeks in Silicon Valley, factory workers in Georgia, gay professionals
in New York" (2005). As such, MA use is not just a problem of the poor and blue collar
individuals. Huber, Ling, Shoptaw, Gulati, Brethren, and Rawson (1997) also found that
MA users were, on average, more than two years younger than cocaine users at the time
of first use (x-barMA users = 2 1 .4). According to SAMHSA (2006), the average age upon
admission to treatment in 2003 was 30.6.
Huber, Ling, Shoptaw, Gulati, Brethren, and Rawson (1997) also recorded the
preferred route of administration for each participant. The following distribution was
found: 55.4% - intranasal; 22.6% - multiple non-injection routes; 13.5% - injection use;
7.2% - smoking; and 1.2% - oral. In a much larger sample of MA users entering
treatment in the state of California (n = 64, 006), it was found that 54.6% of users snorted
the drug and 20.9% were IV users (Cannon, 1996). SAMHSA (2006) reports a recent
shift in this distribution, indicating that nationally 56% of users prefer smoking, 22%
prefer injection, 15% prefer inhalation, 6% prefer oral administration, and 1% prefer
another method. Preferred route of administration has been said to vary greatly from
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region to region (Galloway, Marinelli-Casey, Stalcup, Lord, Christian, Cohen, Reiber, &
Vandersloot, 2000; ONDCP, 2002).
Psychosocial
As of the present, little research has specifically aimed at profiling the
psychosocial correlates of MA (though they have been largely uncovered in many other
ways). Thus, information in this area is somewhat sparse and often inferential.
Many studies and self-reports have indicated that MA is highly correlated with a
loss of inhibitions and an increase in risky behaviors. Perhaps one of the riskiest
behaviors commonly engaged in by MA users is driving while under the influence of the
substance. Logan, Fligner, & Haddix (1998) found that, among 146 MA-related fatalities,
14 % percent were related to traffic accidents. Logan (1996) found that MA induces a
number of behaviors which severely impair the individual's ability to drive safely
including fatigue, hypersomnolence, erratic driving, weaving, and speeding. An increase
in sexual desire, perceived performance, and activity during MA intoxication has also
been supported by a great amount of data (Gawin, 1 978; Bell & Trethowan, 1 96 1 ; Klee,
1993). This leads to risky sexual behaviors such as greater number of sex partners, more
commonly practiced anal sex, and less frequent condom use (Molitor, Truax, Ruiz, &
Sun, 1998; Pach & Gorman, 2002). Gorman, Clark, Nelson, Applegate, Amato, and Scro}
(2003) found MA use in women to be correlated with sex work (i.e. stripping,
pornography, prostitution) as well as chaotic family histories.
MA has become particularly prevalent and influential in the population of MSM
(Wainberg, Kolodny, & Drescher, 2006). The 2001 Urban Men's Health Study, reported
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that more than 1 0% of MSM surveyed in both Los Angeles and San Francisco endorsed
MA use (Stall Paul, Greenwood, Pollack, Bein, Crosby, Mills, Binson, Coates, &
Catania, 200 1 ). MA has become an especially common feature at urban dance-parties
known as "circuit parties." Typically attended by MSM, as many as one third of attendees
at these events report using MA (Reback & Grella, 1999; Mattison, Ross, Wolfson, &
Franklin, 2001 ; Mansergh, Colfax, Marks, Rader, Guzman, & Buchbinder, 200 1 ).
Yet another unfortunate psychosocial characteristic which is common amongst
MA users is interpersonal violence (Pach & Gorman, 2002). Cohen, Dickow, Homer,
Zweben, Balabis, Vandersloot, and Reiber (2003) examined this phenomenon in a sample
of 1 0 1 6 MA users enrolled in a multi-site treatment project. Their findings were startling.
85% of the women, and 70% of men, surveyed reported being victims of physical
violence. Men were most likely to experience violence from strangers, friends, and
parents, while the most common source for women was partners. According to these
authors, "interpersonal violence is a characteristic of the lifestyles of the majority of
persons entering treatment for MA dependence." Although inferences can be made, this
study did not address the likelihood of the MA users themselves being perpetrators of
violence. The authors also note that the extent to which MA specifically (as compared
with other drugs) contributes to this phenomenon. As was mentioned previously,
parenting skills appear to diminish very quickly with MA addiction. As such, child abuse
and neglect are very common features of the homes of MA users (Altshuler, 2005). This
abuse includes exposure to toxic chemicals and fumes as well as more straightforward
physical and sexual abuse and neglect. As mentioned, homicidal ideation as well as
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suicidal ideation (self-directed aggression), are also known correlates of MA use (NIDA,
1996; Kalechstein, Newton, Longshore, Anglin, van Gorp, & Gawin, 2000). In a study of
146 deaths in which MA was detected in the blood, 27% had resulted from homicide and
15% from suicide (Logan, Fligner, & Haddix, 1998). Baberg, Nelesen, and Dimsdale's
(1996) study found AP users more likely than non-users to be admitted to the hospital for
suicide attempts. Moril, ltol, Kita, Toshiko, and Sawaguchil (2004) found that high doses
of MA induced self-injurious behavior when administered to rats.
Some additional psychosocial consequences may be more universal to drug users
in general. These include job loss and interpersonal problems (Morgan & Beck, 1997).
Though not specifically delineated, Pach and Gorman (2002) found that a number of
social, educational, and occupational difficulties are highly associated with MA use.
These types of problems may relate to "amotivational syndrome," a symptom typically
associated with marijuana use, but also apparent as a residual symptom of MA abuse
(Ashizawa & Saito, 1996). Polysubstance abuse is also quite common amongst MA
users. Huber, Ling, Shoptaw, Gulati, Brethren, and Rawson ( 1997) found that the most
commonly co-abused substance amongst 500 MA users was marijuana (56.2% reporting
use in the past year). Surprisingly lower numbers, however, were found for cooccurring
alcohol abuse. Just 22.5% of this sample reported using alcohol more than once weekly
(compared to 31.1% of cocaine users), and an astonishing 33. 8% reported that they never
use alcohol (compared to 20.1 % of cocaine users). 10. 8% of the MA-using group also
reported using cocaine, and 6.4% had used hallucinogens or PCP within the past year.
Only 4.6% had used opiates and 2. 8% had used barbiturates. In the study by Peck,
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Shoptaw, Rotherman-Fuller, Reback, and Bierman (2005) referenced earlier, just 1 1 % of
1 55 MA-dependent MSM met criteria for alcohol abuse or dependence and 1 2.9% met
criteria for dependence for a substance other than amphetamines.
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Chapter 3:
Purpose, Hypothesis, and Procedures

Purpose
The purpose of the present study was to determine the extent of the influence that
MA use exerts on psychosocial functionality as measured by the 27 subscales of the
Multi-Problem Screening Inventory (MPSI; Hudson, 1990). The areas assessed by this
instrument include: depression, self-esteem, partner problems, sexual discord, child
problems, mother problems, father problems, personal stress, friend problems, neighbor
problems, school problems, aggression, problems with work associates, family problems,
suicide, non-physical abuse, physical abuse, fearfulness, ideas of reference, phobias,
guilt, work problems, confused thinking, disturbing thoughts, memory loss, alcohol
abuse, and drug abuse. A second purpose of this study was to generate information which
would equip addictions treatment practitioners with some a priori information about the
MA-using clients that come through their doors. Although these individuals will have
likely accumulated much of this knowledge through their practice with these clients and
research on the topic, this study provides a consolidated resource to which counselors can
easily tum in order to organize and solidify their expectations for areas to address during
intake interviews as well as potential targets and obstacles of treatment.
Hypothesis
The overall hypothesis of the current study is that MA will have a statistically
significant effect on psychosocial functionality. This hypothesis must, however, be
broken down due to the nature of the data collected. Psychosocial functionality will be
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divided into the 27 areas of the MPSI and will not itself be measured directly. Further, the
"effect" of MA will be divided into three separate "sub-hypotheses." Based on the
information obtained through literature reviewed above, it is predicted that differences
between the experimental and control group will appear in nearly every area of the MPSI.
Thus, for each and every subscale, hypothesis # 1 will be stated as: The MA-using group
will report a mean score which is higher that that of the non MA-using group, to a
statistically significant degree. Additionally, however, there are areas in which mean
scores for the MA-using group are expected to lie above the clinical cutting score,
indicating a "problem" for that scale. For most of the 27 scales, the cutoff score is 30.
The only exceptions are the suicide scale (with a cutoff score of 1 5) and the physical
abuse scale (with a cutoff score of 5). To sum up these predictions, hypothesis #2 applies
only to the subscales listed below and is stated as: The MA-using group will report mean
scores on certain scales which lie above the clinical problem threshold. These specific
predictions are delineated and justified below:

Depression - Given the devastating neurochemical impact of MA use on mood
modulating transmitters such as dopamine and serotonin, symptoms of depression are
likely to be characteristics of nearly all of our MA users. In addition, the individuals
surveyed are, for the most part, currently abstinent from MA, meaning that they are no
longer experiencing the mood enhancing properties previously obtained through use. As
this abstinence is less than one year old for these individuals, it is also likely that natural
mood regulation has not yet returned to them.

Self-esteem - As a correlate of depression, decreased self-esteem is expected to be
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a problem for many of the MA using individuals. This likelihood is also increased by the
decline of physical appearance associated with MA use, cited earlier.
Child problems - Given the horrific circumstances under which many of the
children of MA addicts live, it is expected that the experimental group will score high in
this area. Questions which comprise this construct in the MPSI refer to mostly relational
issues such as "I wish I did not have this child," and "I dislike my child," etc. (Hudson,
1 990, p. 2).
Personal stress - The lives of MA users are often filled with anxiety. They worry
about where there going to get their next fix, making ends meet, losing their jobs, homes,
and children, being discovered by the police, and losing control of their lives. As cited,
these types of fears often tum into full blown paranoia. It is thus assumed that the MA
using group will exhibit clinically significant problems in this area.
Aggression - MA use is highly correlated with being a victim of interpersonal
violence and loss of inhibitions. In addition, MA has become a leading cause of violent
crime. All indications, whether empirically-based or anecdotal, seem to imply that MA
users are likely to exhibit heightened aggression.
Suicide - As another correlate of depression, it is hypothesized that suicidal
ideation will be pronounced among MA users. The prolonged period of biological
reparation during which recovering MA users are biochemically unable to experience
pleasure or reward makes resorting to suicidal ideation and intent more and more likely.
Physical & non-physical abuse - As was cited in regard to several studies earlier,
MA users at an extremely high risk for being victims of physical abuse. It is predicted,
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based on the statistic that 85% of women and 70% of men entering treatment for MA
abuse have been victims of physical violence (Cohen, Dickow, Homer, Zweben, Balabis,
Vandersloot, and Reiber, 2003), that this area will be of particular concern for MA users.
Further, as non-physical abuse often precedes, follows, and co-occurs with physical
violence, that area is also expected to correlate with MA use.
Fearfulness, ideas ofreference, confused thinking, and disturbing thoughts - As
features of paranoia and psychosis it expected that abstinent MA users will show elevated
MPSI scores in each of these areas when compared with non-MA users. According to the
lecture by Dr. Richard Rawson cited earlier (personal communication, March 20, 2006),
the development of these features happens more often than not in chronic users.
Guilt - The behavior of a person addicted to MA is often limited to several goals,
such as obtaining more of the drug, keeping oneself alive, and keeping oneself out ofjail.
As such, people in recovery are likely to be extremely ashamed of some of the things that
they have done in these pursuits, including stealing, neglecting children, or hurting those
that they have cared about. It is thus expected that guilt will be a common problem
amongst the group of recovering MA users.
Work Problems - As a result of the extreme physical and behavioral
consequences of prolonged MA use, the emergence of problems at work seems probable.
As mentioned previously, however, many individuals (especially those that do not inject
the drug) are able to hold steady jobs for many years while using. Some even use the drug
for its work performance-enhancing properties. This construct on the MPSI, however,
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relates more to attitude toward work, than job performance or stability. Thus, significant
problems are predicted in this area.

Memory Loss - Users of most drugs are prone to blackouts as well as impairment
of working memory function, and MA is no exception. In addition research on the drug's
effects on hippocampal volume indicate that deficits in this domain are quite likely.

Alcohol & Drug Abuse - Intuitively, one would assume that individuals in
treatment for MA use will report clinically significant problems on the scale for drug
abuse. The common practice of polysubstance abuse increases this likelihood. Finally,
although most research indicates that no more that 1/3 - 1/5 of MA users also consume a
significant amount of alcohol, it is expected that sufficient problems associated with
alcohol use will be reported to cross the cutoff threshold for this subscale as well.
Finally, a hypothesis is made regarding the connection between degree of
addiction to MA and psychosocial functionality. Since no empirically validated
instrument for evaluating strength of addiction was administered, this analysis will be
limited to the results of the question on the MA-use questionnaire which asked
participants to rate the severity of the cravings that they experience for MA on a 1-5
scale. Hypothesis #3 is thus stated as: There will exist a positive correlation between
severity of craving for MA reported and score on each of the 27 subscales of the MPSI.
For individuals in the control group who report having never used MA, severity of
craving was assumed to be the lowest possible ( a score of " I " - virtually no craving).
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Procedures
Source ofparticipants.

It must first be stated that the execution of this study was approved in writing by
the institutional review board of the University of Tennessee, the committee for this
thesis, as well as each of the agencies involved. As mentioned, this study compares
individuals with a history of MA use with those that have never used the drug. Inclusion
in the MA-using group was established on the basis of being over the age of 1 8 and
having used the drug within the past year. This group was assembled from caseloads of
current clients at several substance abuse treatment agencies located in the east Tennessee
region. Although a number of different agencies granted approval to participate in this
study, only two ended up supplying participants. The Council for Alcohol and Drug
Abuse Services (CADAS), located in Chattanooga, 1N, supplied the majority ( 1 3) of
participants for the MA-using group. Specifically, these individuals were currently in
treatment through the OASIS, a residential half-way house program for individuals
transitioning from prison back to community life. The remaining two individuals were
recruited through Genesis Recovery Center in Lake City, 1N, a voluntary residential drug
and alcohol rehabilitation facility. Thus, although individuals in the experimental group
must have used MA within the past year, it is presumed that they are not currently using.
However, the length of abstinence, as well as the duration of previous use, is unknown.
The comparison group in this study was established based on being over the age of 1 8
and having never used MA. This group was assembled through the University of
Tennessee College of Social Work's undergraduate program. Members of both groups
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were permitted to be both male and female, and were not selected or excluded on the
basis of any specific cultural, racial, or ethnic background or socioeconomic status.
Procedures for recruitment of both groups are described in detail in the next chapter.
Instruments.
The three instruments used in this study were the MPSI (Hudson, 1 990), a
methamphetamine-use questionnaire, and a demographic information sheet. Hudson and
McMurtry ( 1 997) examined the reliability and validity of each of the 27 subscales. It was
found that the scales which comprise the MPSI have "good to excellent reliability," and
that the instrument itself is "strong enough in terms of its measurement error
characteristics to recommend it for use in a wide range of research applications," and is
"acceptable in terms of its content, factorial, and construct validity" (p.95). No research
was found on the appropriateness of the clinical cutting scores used on the MPSI. The
methamphetamine-use questionnaire (Appendix A) and the demographic information
sheet (Appendix B) were created by the researcher specifically for the current study. As
such, no information as to the psychometric properties of these instruments exists.
Recruitment.
Potential participants for the experimental group were surveyed through oral
communication with supervisors at the treatment agencies cited previously. These
individuals were then asked to check computer records of client roles, and consult clinical
staff, to identify persons with a history of methamphetamine use. It is noted that the
identification of MA users was unexpectedly challenging. Nearly every substance abuse
related agency in the Knox County, TN area was contacted in regard to this study.
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Innumerable conversations were had with directors of agencies who stated that they
rarely saw MA users, as crack was still the primary drug problem in this area. This may
be attributable to the current state of the eastward spread of MA, having not yet fully
overtaken the TN area, or the fact that crack still tends to be dominant in urban areas over
other stimulants due to its price and availability. Only once the search for participants
was extended to surrounding areas were MA users finally located. Even then, users were
identified only one, or a few, at a time; it was painstaking to assemble even the relatively
small sample used in this study.
Each participant was then approached during a regularly scheduled treatment
session by his or her treatment professional and informed about this study. The
participant was told at this time that the study was part of a master's thesis on drug use
and that they met the requirements for voluntary participation. They were also informed
that the study would require about one hour of their time and that they would receive $ 1 0
incentive (in the form of a gift certificate, valid for the purchase of licit goods only) to
compensate them for participation. In order to assure that no coercion to participate,
positive or negative, was introduced by staff, the client was simply asked if they would
allow the researcher to contact them by phone to discuss the study further. As such, the
person's therapist was never aware of whether or not the client had agreed to participate.
At the time of this initial meeting with agency staff, the client was asked to sign a brief
consent form giving the treatment professional permission to transmit his or her name
and phone number to the researcher by telephone (or in person).
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Upon receiving confirmation of permission to contact the client from the
treatment professional, the researcher did so by phone, and spoke to the individual about
the study. No answering machine or voice mail messages were left regardin g the study.
Once verbal consent to participate was obtained, a meetin g was scheduled at which
written consent was obtained and the instruments were administered. This meeting took
place at a location within the agency in which the individual 's treatment professional was
unlikely to observe it.
Individuals in the control group, recruited through the University of Tennessee's
College of Social Work, were solicited in a slightly different manner. In order to open the
study to as man y students as possible, a flier was distributed via email to all students
enrolled in undergraduate social work courses. These fliers informed students of the $ 10
incentive, the survey-based format, and the required time commitment and asked that
interested students contact the researcher by email to schedule an appointment time. In
addition to circulation of fliers, the researcher presented the study (initially providing
only the same in formation included on the flier) in the undergraduate class of Ms.
Heather Parris, MSSW, once again asking that interested students volunteer via email. At
the agreed upon time, the principal investigator met the student in student lounge in
Henson Hall.
Administration.

At the time of the scheduled appointment, the participants met the researcher in
private, at the agreed-upon location , to discuss the specifics of the study including the
purpose, the nature of the questions to be asked, and the associated risks and protective
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measures, and were given the opportunity to be left alone to consider and sign the
informed consent statement (Appendix C). At this time, the participant was also given
the study information sheet. Once the informed consent form was signed, it was be
collected by the researcher, placed into a locked briefcase. The consent forms were never
attached to, and never referred in any way to, a specific data sheet.
The office in which this meeting took place was average sized (approximately 1 21 5' x 1 2- 1 5') and was in a location in which the participant' s treatment professional, or
professor, was unlikely to witness the meeting. The office was set to a comfortable
temperature and had a minimal number of distracting items in view. Before the
participant arrived, the researcher will have ascribed an arbitrary identification number to
the participant identification sheet, the demographic information sheet, both of the survey
instruments, and the manila envelope into which the results were eventually placed by the
client. The participant was greeted in a friendly and welcoming manner, seated with at
least a 1 ' x 1 ' writing surface in front of them, and then briefing was begun by reading
section one of the briefing script (Appendix D).
Next, the participant was given the manila envelope and the demographic
information sheet and read section two of the briefing script. Then, the participant was
given time to fill out the demographic information sheet. Next, the researcher explained
that testing was going to begin by reading section three of the briefing script.
The participant was then given time to fill out the MPSI and the
Methamphetamine-Use Questionnaire in private. When finished, he or she met the
researcher, obtained the $ 1 0 gift certificate, and was free to go. With the participant still
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present, the researcher collected the manila envelope, placed a tamper-evident sticker
onto the seal, and placed it into the locked briefcase containing the informed consent
sheet. At no time was the briefcase out of the sight of the researcher or left unlocked. The
sealed manila envelope was then placed in a secure filing cabinet at the researcher's
home office and was never be opened by the researcher.
Computerization and analysis ofdata.
The final step in this procedure was the statistical analysis of the data. The
computerization of the data was done by a third-party assistant so that the researcher
never saw the data sheets for an individual and would have thus not been able to, under
subpoena, connect any individual to any set of responses by any means. This research
assistant was made to sign the research team member's pledge of confidentiality form.
Data was entered into a Microsoft Excel file using a secure computer located in the social
work building (Henson Hall). Data was never saved to the computer's hard drive. Instead,
a USB flash-drive stick was used. The data sheets, of course, never contained any
participant identifiers and the variables, as they were entered into the computer, were
labeled using nonsense syllables rather than the actual variable names. In addition, the
computer being used was password and firewall protected, and any internet connection
was disabled prior to use. During data entry, the office door was kept closed and locked
and no visitors were admitted. After computerization of data was complete, the assistant
placed the data sheets back into the manila envelopes, sealed them with a new tamper
evident sticker, placed them into a locked briefcase, and returned them to the researcher
along with the flash dive containing the Excel files. The paper data sheets will be kept in
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a secure filing cabinet at the researcher's home office for five years following the
completion of the study, at which time they will be shredded. Once the researcher had
received the password-protected USB flash-drive stick containing the raw data, he scored
the MPSI' s and performed the statistical analysis at his home office. Once again, analysis
of data took place in private, and was never saved to the computer's hard drive. This
computer as well was password and firewall protected. MPSI's were scored according to
the procedures included with the instrument. Subscales on which a respondent had
skipped 20 or more percent of the questions were considered missing. Frequencies were
calculated for the occurrence of substance use, gender, race, and marital status.
Descriptive statistics were computed for age, severity of craving, and scores for each
group on each MPSI subscale. Differences in means were examined between meth users
and non users across each of the 27 subscales of the MPSI using independent samples t
tests. Correlation between severity of MA cravings and MPSI subscale score was
calculated using the Spearman rank-order correlation method.
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Chapter 4: Results

Missing Data
For the demographic information questionnaire and the MA-use questionnaire, no
missing data was observed. On the MPSI, however, a significant amount of missing data
needed to be addressed. Table 1 shows the percentages of missing MPSI data for the MA
and non MA-usin g groups on each subscale. For the most part, these gaps were expected
based on the instructions given to respondents to answer with an ''x" when an item or a
subscale did not apply to them. As a result of this sys tematic, or meaningful, punctuation
of the data set, the concepts ofrandom versus non-ignorable missingness did not apply.
Consequently, statistical methods such as mean substitution, multiple imputation , etc.,
did not make sense. Rather, one of two scenarios seemed the most plausible and led the
researcher to two distinct methods of handling the problem:
The first possibility was that the respondent left a subscale blank because the
construc t itselfdid not apply to them. For example, a participant who did not have
children would have no basis for responding to the "child problems" subscale. This type
of missin g data, as would be expected, was much more common than the next. The
subscales which were placed into this category of missing data were: partner problems,
sexual discord, child problems, mother problems, father problems, friend problems,
neighbor problems, school problems, problems with work associates, and work problems.
In order to more accurately examin e the effects of MA, cases which did not contain data
for these scales were excluded from the analysis through list-wise deletion . The reason
that this was done is that it is of more use to know what kind of problems MA-users that
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Table I
Missing Values by Group (%)

Subscale
Depression
Self-Esteem
Partner Problems
Sexual Discord
Child Problems
Mother Problems
Father Problems
Personal Stress
Friend Problems
Neighbor Problems
School Problems
Aggression
Work Associates
Family Problems
Suicide
Non-Physical Abuse
Physical Abuse
Fearfulness
Ideas of Reference
Phobias
Guilt
Work Problems
Confused Thinking
Disturbed Thinking
Memory Loss
Alcohol Abuse
Drus Abuse

MA Users
0
0
60
66.7
46.7
26.7
1 3 .3
0
0
33.3
67.7
0
26.7
0
0
0
0
0
0
0
0
33.3
0
0
0
0
0

Non MA Users
0
0
1 1 .8
23 .5
76.5
5.9
1 7.6
0
0
1 7.6
0
5.9
1 7.6
0
0
1 1 .8
1 7.6
0
0
0
0
23.5
0
0
0
47. 1
47. 1
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DO have children are having with them, than to assume that those without children would
have "O" problems with them if they did. The limitation of this method of handling the
missing data is that the sample size for several of these scales was greatly reduced.
In a second pattern of missing data, it was believed that the respondent felt that
the subscale did not apply to them based on the lack of a given trait or problem. In other
words, rather than responding with the lowest possible scores for depression, a "happy"
participant may have simply skipped that scale thinking, "depression does not apply to
me." The subscales which fall into this category of missing data were: depression, self
esteem, personal stress, aggression, family problems, suicide, non-physical abuse,
physical abuse, fearfulness, ideas of reference, phobias, guilt, confused thinking,
disturbed thinking, memory loss, alcohol abuse, and drug abuse. For these types of scales,
it was assumed that lack of response indicated lack of problem in that area and a "O" was
substituted for that case. The reason for doing so was to ensure that individuals WITH
problems in these areas were not overrepresented as a result of the lack of response by
other participants. The limitation of this procedure was that it required that an inference
be made about the reason someone did not respond, and as to what they might have
responded had they done so.
Participants
In all, 35 individuals were surveyed for this study and 32 were included in data
analysis. The three individuals excluded had indicated that they had used MA in their
lifetime, but not within the past year. As these individuals did not meet criteria for
inclusion in either group, their data was not included in this analysis. However, an
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additional analysis was conducted including these individuals in the MA-using group and
no major alterations in results were obtained. Of the remaining 32, 1 5 were considered
past-year MA users and 1 7 were considered non-MA users. Two of participants included
in the MA-using group reported MA use within the past 30 days.
Analysis of income differences between groups was not conducted due to inherent
differences between these two groups which rendered such information irrelevant. First,
the control group' s status as students made placing them in the position of being an
indicator of a typical non-MA user's income nonsensical. This is because many students
do not have income at all. In addition, it is unclear whether or not numbers collected from
this group included the student's parents' income. Finally, a number of the MA-using
individuals indicated distribution of MA as either their primary or a supplemental
income. This made extrapolation of the person's licit income impossible. All of these
factors distorted the reliability of assuming a person's income to be a representation of
their socio-economic status, the variable of true interest.
Across the demographic variables that were analyzed, the two groups were quite
different. The demographic information collected is summarized in Table 2. Exactly in
line with the findings of other research, the MA users were 60% male, 40% female (n =
1 5). The non MA-using group (n = 1 7) was 1 00% female. This reflects the largely
(94. 1 %) female student body within the University of Tennessee, Knoxville College of
Social Work's undergraduate program in general (data includes only juniors and seniors;
G. Cox, personal communication, July 7, 2006). The average age for MA users was 32.9
(SD = 9.8), as compared with 23.7 (SD = 7.5) for non users. Between-group differences
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Table 2

Demographic Information
Age
Mean
SD
Gender (male= l )*
Ethnicity (white= } )*
Marital status (married = 1 )*

MA Users

Non Users

32.90
9.80
0.60
1 .00
0. 1 3

23 .70
7.50
0.00
0.59
0.2 9

* For ease of reading, the marital status and ethnicity variables
were rendered dichotomous, indicating married versus unmarried
and white versus non-white. For these, and for gender, the
numbers listed are the proportions of respondents reporting the
trait coded "l ."
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were also dramatic for marital status and racial/ethnic background. 53% of MA users
were divorced or separated and 33% were single, while only 1 3% reported being married.
The non users were 71 % single and 29% married, with no respondents reporting being
divorced or separated. 1 00% of the MA-using group was Caucasian. Slightly more racial
diversity was observed in the control group with 59% Caucasian, 29% African American,
and 1 2% reporting both Caucasian and African American genealogy.
The average severity of craving score ( on a 1 -5 scale) for MA users (n = 1 5) was
2.93 (SD = .88), with a score of 3 indicating a moderate craving. As non-MA users (n =
1 7) reported, or were assumed to have, no cravings for the substance, there existed a
statistically significant difference between the two groups according to an independent
samples !-test [t(30) = -9.040, p = .000]. Table 3 displays the distribution of drugs (other
than MA) regularly used by each group. 73 .3% of MA users reported that they consider
MA their "primary drug of choice" meaning that they "use it much more regularly than
the others." The most commonly co-abused substance among MA users was marijuana
(47. 1 % reporting use), closely followed by cocaine (46.7% .reporting use). Amongst non
users, abstinence from drugs and alcohol was the most common response (47 . 1 % of
respondents), followed by alcohol and marijuana (35.3% of respondents reporting use for
each). Non users were, in fact, slightly more likely to use alcohol than MA users.
Results ofHypothesis Tests

Table 4 summarizes the descriptive statistics collected and indicates that scales on
which either group exceeded the clinical cutting score. To compare the mean scores of
MA users with those of non users, an independent samples I-test was conducted for each
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Table 3
Percentage of Respondents Reporting Substance Use

Substance
MA/AP
Alcohol
Marijuana
Cocaine
Crack
Heroin
Hallucinogens
Prescription Pills
None

MA Users
1 00
33.3
47. 1
46.7
20
6.7
26.7
40
20

Non MA Users
0
35.3
35.3
0
0
0
5.8
5.8
47. 1

53

Table 4
Summary ofDescriptive Statistics

MA
users
Subscale
Depression
Self-Esteem
Partner Problems
Sexual Discord
Child Problems
Mother Problems
Father Problems
Personal Stress
Friend Problems
Neighbor
Problems
School Problems
Aggression
Work Associates
Family Problems
Suicide
Non-Physical
Abuse
Physical Abuse
Fearfulness
Ideas of
Reference
Phobias
Guilt
Work Problems
Confused
Thinking
Disturbed
Thinking
Memory Loss
Alcohol Abuse
Drug Abuse

Non
users

n
15
15
6
5
8
11
13
15
15

Mean
42.5
33. 1
56.8
36.8
9.7
20.8
23
43 . 1
3 1 .3

SD
17.1
14.4
26.0
1 7.0
7.3
20.2
1 8.0
23 .6
1 4.0

n
17
17
15
13
4
16
14
17
17

Mean
26.3
30.6
20.9
3 0�2
25.3
24.6
26.7
27.4
23.8

SD
1 3 .2
13.1
23 .5
1 6.2
1 1 .4
1 7.6
24.7
22.8
1 6.7

10
5
15
11
15
15

59
46. 1

30
3 2 .6
29.8
6.4

24.4
26.9
23 .6
1 9.9
2 1 .9
1 1 .4

14
17
17
14
17
17

36.0
3 0.9
9.4
23 .4
32.4
4.3

22.8
1 2.6
8. 1
1 5. 1
1 9.6
7.5

15
15
15

13.1
1 .4
20.4

23 .2
3 .6
1 1 .9

17
17
17

6.2
0.0
8.4

9.5
0.0
8.3

15
15
15
10

25
3 2.9
44.3
27.2

1 7.6
1 4.6
19.6
14.5

17
17
17
13

4.9
1 6.6
1 8.3
21.1

6.7
1 1 .3
1 8.2
12.1

15

49.5

23.3

17

1 8.5

1 7.2

3 1 .6
3 7. l
20.5

25 . 1
26.6
27.6
26.5

17
17
17
17

14. 8
12.9
5.8
2.4

1 8.9
10.1
1 1 .2
4.9

15
15
15
15

-

Note. Scores above the clinical cutting score are shaded
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MPSI subscale. Results of these tests are shown in Table 5 . For each of these tests, alpha
was set at .05 due to the exploratory nature of this study and the associated desire to
avoid type II errors. For this same reason, no adjustment of significance level (such as
Bonferroni's correction) for multiple tests was computed. However, the exclusion of this
adjustment procedure produced an approximately 75% chance that at least one type I
error exists in the results reported. This is, however, likely an overestimate of the
probability of type I error, as the equation used to compute this figure assumes that all 27
tests are independent of one another, an assumption which is certainly not valid. This
high type I error rate was deemed acceptable due to the lack of serious consequences
associated with a false detection of a difference.
As a result of the employment of list-wise deletion on certain subscales, the n
value was reduced in some of the analyses. Thus, the n which was actually used in each
analysis is reported for each group on each subscale. To analyze the correlation between
the ordinal variable severity of craving and MPSI subscale score, a Spearman rank-order
correlation was used; alpha was set at .05 for this test as well. Results of these tests
appear in Table 6.
Depression - A mean depression score of 42.5 (SD = 17 . 1 ) was obtained for the
MA-using group (n = 1 5). This was 1 6.2 points higher than the mean of 26.3 (SD = 1 3.2)
obtained for the non MA-using group (n = 1 7), indicating a statistically significant
difference [t(30) = 3 .02, p = .005). This allowed for a rejection of null hypothesis # 1 on
this scale. Hypothesis #2 was also confirmed for depression, with the mean score for MA
users lying 1 2.5 points above the clinical cutting score. Hypothesis #3 was also supported
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Table 5
Results of I-tests

Self-Esteem
Partner Problems
Sexual Discord
Child Problems
Mother Problems
Father Problems
Personal Stress
Friend Problems
eighbor
Problems
School Problems
ggre 10n
Work Associates
Family Problems
Suicide
Non-Physical
Abuse
Ph kal Abuse
earfulness
Ideas f
Reference
:Phobias
Guil

Work Problems
Confused
hin . ing
rn turbed

Th ·nking

Mc:mory Loss
Alcohol Abuse

0.5 1 7
3 .076
0.76 1
-2.9J 5
-0.5 1 5
-0.43 8
1 .907
1 .360
2.362
1 .8 1 8
3 .226
1 .323
-0.355
0.6 1 9

22
20
23
30
30

0.027
0.084
0.-005
0. 1 99
0.725
0.540

1 .087
1 .482
3 .320

1 8. 1
14
30

0.29 1
0. 1 6 1
0.002

4 . 1 63
3 .558
J . 896
1 .099

17.5
30
30
21

< H )O i
0 0� 1
Q.OO J

4.3 1 4

30

0.000

2 . � 54
3 .334
1 .926

1 7.S

30

-0.0J(}

9.7 1 2

1 6.9

18
1 4.8

Note. Statistically significant findings are

shaded

0.284

0.004
0.070
0.()()0__

56

Table 6
Results ofRank-Order Correlation/or Severity of Craving

Sexual Discord
Chi ld Problems
Mother Problems
Father Problems
Person a I Stress
Friend Problems
, �,gl1bor Problems----�···""'"'·""'"""""""''"'"'"--�--School Problems
A re sioo
Work Associates
Family Problems
Suicide
Non-Ph skal Abuse
Physical Abu e
Fe rfuJne�s
( de· of Reference
hobias
Guilt
Work Problems
Confu ed h inking
Di rurbed Thinking
Meme Lo
Alcohol Abuse
. Dru'g Abuse

------

-----�------

M--·---

---�-����-------·24

-..-.....--------�-

Note. Statistically significant findings are shaded

0.606--0. 1 57
-0.602
----0.099
-0.083
0.3U ]
0.27
0.454
--- 0.2 1 4
, : 5 89
0.322
-0. 1 3 5
0.046
-0. 1 I 6
0.33 8
0.562
0.752
0.58 1
0.6 1
0.407
0. 54
0.4 1 7
· O.SSJ
0.07
0.365

22
32
25
32
32
32
32
32
32
32
32
23
:l2
32
32
32
32

��-

---------
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for this scale, with the Spearman' s Rho test showing a significant correlation between
self-reported severity of craving and MPSI score for depression (rs = .447, p = .005).
Severity of cravings, thus, accounted for 20.0% of the variance observed for depression.
Self-esteem - A mean self-esteem score of 33. 1 (SD = 14.4) was obtained for the

MA-using group (n = 1 5). This was 2.5 points higher than the mean of 30.6 (SD = 1 3 . 1 )
obtained for the non MA-using group (n = 1 7). This difference, however, was not
statistically significant [t(30) = .5 1 7, p = .609). Thus, null hypothesis # 1 failed to be
rejected for this scale. Hypothesis #2 was confirmed for self-esteem, with the mean score
for MA users lying 3 . 1 points above the clinical cutting score. The mean score for non
MA users on this scale, however, was also above the clinical cutting score, by .6 points.
Hypothesis #3 was not supported for this scale as no significant correlation between
severity of craving and self-esteem was observed (rs = .0 1 9, p = .459).
Partner problems - A mean partner-problems score of 56.8 (SD = 26.0) was

obtained for the MA-using group (n = 6). This was 35. 1 points higher than the mean of
20.9 (SD = 23.5) obtained for the non MA-using group (n = 1 5), indicating a statistically
significant difference [t(l 9) = 3.076, p = .006). This allowed for a rejection of null
hypothesis # 1 on this scale. Though not hypothesized, the mean score for MA users was
26.8 points above the clinical cutting score for this scale, indicating the presence of a
significant problem. Hypothesis #3 was also supported for this scale, with the Spearman's
Rho test showing a significant correlation between self-reported severity of craving and
MPSI score for partner problems (rs = .606, p = .002). Severity of cravings, thus,
accounted for 36. 7% of the variance observed for partner problems.
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Sexual Discord - A mean sexual-discord score of 36.8 (SD = 17.0) was obtained
for the MA-using group (n = 5). This was 6.6 points higher than the mean of 30.2 (SD =
16.2) obtained for the non MA-using group (n = 13). This difference, however, was not
statistically significant [t( 16) = .761, p = .458). Thus, null hypothesis #1 failed to be
rejected for this scale. Though not hypothesized, the mean score for MA users was 6.8
points above the clinical cutting score for this scale. The mean score for non MA users on
this scale, however, was also above the clinical cutting score, by .2 points. Hypothesis #3
was not supported for this scale as no significant correlation between severity of craving
and sexual discord was observed (r s = . 157, p = .267).
Child problems - A mean child-problems score of 9. 7 (SD = 7 .3) was obtained for
the MA-using group (n = 8). This was 15 .6 points below the mean of25.3 (SD = 1 1.4)
obtained for the non MA-using group (n=4), indicating a statistically significant
difference in the opposite direction of that which was expected [t( l O) = -2.935, p = .0 15).
Thus, null hypothesis # 1 failed to be rejected for this scale. Hypothesis #2 was not
substantiated for child problems, as the mean score for MA users was 20.3 points below
the clinical cutting score. Though much closer, the non MA-using group did not exceed
the cutting score either. Hypothesis #3 was rejected for this scale, with the Spearman's
Rho test showing a significant correlation between self-reported severity of craving and
MPSI score for child problems, in the opposite direction expected (r s = -.602, p = .0 19).
Mother problems - A mean mother-problems score of 20.8 (SD = 20.2) was
obtained for the MA-using group (n = 1 1). This was 3.8 points below the mean of 24.6
(SD = 17.6) obtained for the non MA-using group (n = 16). This difference, however,
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was not statistically significant [t(25) = -.5 1 5, p = .61 1 ). Thus, null hypothesis #1 failed
to be rejected for this scale. Hypothesis #3 was not supported for this scale as no
significant correlation between severity of craving and mother problems was observed (rs
=

-.099, p = .3 1 1 ).
Father problems - A mean father-problems score of 23.0 (SD

=

1 8.0) was

obtained for the MA-using group (n = 1 3). This was 3 .7 points below the mean of 26.7
(SD = 24.7) obtained for the non MA-using group (n = 1 4). This difference, however,
was not statistically significant [t(25) = -.438, p = .665). Thus, null hypothesis # 1 failed
to be rejected for this scale. Hypothesis #3 was not supported for this scale as no
significant correlation between severity of craving and father problems was observed (rs =
-.083, p = .340).
Personal stress - A mean personal-stress score of 43. 1 (SD = 23 .6) was obtained
for the MA-using group (n = 1 5). This was 1 5.7 points higher than the mean of 27.4
(SD = 22.8) obtained for the non MA-using group (n = 1 7). This difference, however, fell
just below the threshold of statistical significance [t(30) = 1 .907, p = .066). Thus, null
hypothesis # 1 failed to be rejected for this scale. Hypothesis #2, however, was confirmed
for personal stress, with the mean score for MA users lying 1 3 . 1 points above the clinical
cutting score. Hypothesis #3 was also supported for this scale, with the Spearman' s Rho
test showing a significant correlation between self-reported severity of craving and MPSI
score for personal stress (rs .30 1 , p = .047). Severity of cravings, thus, accounted for
=

9 .1 % of the variance observed for personal stress.
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Friend problems - A mean friend-problems score of 31.3 (SD = 14.0) was
obtained for the MA-using group (n = 15). This was 7.5 points higher than the mean of
23.8 (SD = 16.7) obtained for the non MA-using group (n = 17). This difference,
however, was not statistically significant [t(30) = 1.360, p = .184). Thus, null hypothesis
#1 failed to be rejected for this scale. Though not hypothesized, the mean score for MA
users fell 1.3 points above the clinical cutting score, indicating the presence of a
significant problem. Hypothesis #3 was not supported for this scale as no significant
correlation between severity of craving and friend problems was observed (rs = .270, p =
.067).

Neighbor problems - A mean neighbor-problems score of 59.0 (SD = 24.4) was
obtained for the MA-using group (n = 10). This was 23.0 points higher than the mean of
36.0 (SD = 22.8) obtained for the non MA-using group (n = 14), indicating a statistically
significant difference [t(22) = 2.362, p = .027). This allowed for a rejection of null
hypothesis #1 on this scale. Though not hypothesized, the mean score for MA users fell
29.0 points above the clinical cutting score, indicating the presence of a significant
problem. The mean score for non MA users on this scale, however, was also above the
clinical cutting score, by 6.0 points. Hypothesis #3 was also supported for this scale, with
the Spearman' s Rho test showing a significant correlation between self-reported severity
of craving and MPSI score for neighbor problems (rs = .454, p = .013). Severity of
cravings, thus, accounted for 20.6% of the variance observed for neighbor problems.

School problems - A mean school-problems score of 46.1 (SD = 26.9) was
obtained for the MA-using group (n = 5). This was 15.2 points higher than the mean of
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30.9 (SD = 1 2.6) obtained for the non MA-using group (n = 1 7). This difference,
however, was not statistically significant [t(20) = 1 .8 1 8, p = .084). Thus, null hypothesis
# 1 failed to be rejected for this scale. Though not hypothesized, the mean score for MA
users fell 1 6. 1 points above the clinical cutting score, indicating the presence of a
significant problem. The mean score for non MA users on this scale, however, was also
above the clinical cutting score, by .9 points. Hypothesis #3 was not supported for this
scale as no significant correlation between severity of craving and school problems was
observed (rs = .2 1 4, p = . 1 69).
Aggression - A mean aggression score of 30.0 (SD = 23.6) was obtained for the

MA-using group (n = 1 5). This was 20.6 points higher than the mean of 9.4 (SD = 8. 1 )
obtained for the non MA-using group (n = 1 7), indicating a statistically significant
difference [t(1 6.9) = 3 .226, p = .005). This allowed for a rejection of null hypothesis # 1
on this scale. Hypothesis #2 was also confirmed for aggression, with the mean score for
MA users lying precisely at the clinical cutting score. Hypothesis #3 was also supported
for this scale, with the Spearman' s Rho test showing an extremely significant correlation
between self-reported severity of craving and MPSI score for aggression (rs = .589, p =
.000). Severity of cravings, thus, accounted for 34. 7% of the variance observed for
aggression.
Work associates - A mean work-associates score of 32.6 (SD = 1 9.9) was

obtained for the MA-using group (n = 1 1 ). This was 9.2 points higher than the mean of
23.4 (SD = 1 5. 1 ) obtained for the non MA-using group (n = 1 4). This difference,
however, was not statistically significant [t(23) = 1 .323, p = . 1 99). Thus, null hypothesis
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#1 failed to be rejected for this scale. Though not hypothesized, the mean score for MA
users fell 2.6 points above the clinical cutting score, indicating the presence of a
significant problem. Hypothesis #3 was not supported for this scale as no significant
correlation between severity of craving and problems with work associates was observed
(rs = .322, p = .058).

Family problems - A mean family-problems score of 29.8 (SD = 2 1 .9) was
obtained for the MA-using group (n = 15). This was 2.6 points below the mean of 32.4
(SD = 19.6) obtained for the non MA-using group (n = 17). This difference, however,
was not statistically significant [t(30) = -.355, p = .725). Thus, null hypothesis #1 failed
to be rejected for this scale. Though not hypothesized, the mean score for non MA users
indicated presence of a significant problem in this area, falling 2.4 points above the
clinical cutting score. Hypothesis #3 was not supported for this scale as no significant
correlation between severity of craving and family problems was observed (rs = -.135, p =
.231).
Suicide - A mean suicide score of 6.4 (SD = 1 1 .4) was obtained for the MA-using

group (n = 15). This was 2.1 points higher than the mean of 4.3 (SD = 7.5) obtained for
the non MA-using group (n = 1 7). This difference, however, was not statistically
significant [t(30) = .619, p = .540). Thus, null hypothesis # 1 failed to be rejected for this
scale. Further, hypothesis #2 was rejected for suicide, with the mean score for MA users
lying 8.6 points below the clinical cutting score. Hypothesis #3 was not supported for this
scale as no significant correlation between severity of craving and suicide was observed
(rs = .046, p = .402).
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Non-physical abuse - A mean non-physical abuse score of 1 3 . 1 (SD = 23 .2) was
obtained for the MA-using group (n = 1 5). This was 7. 1 points higher than the mean of
6.2 (SD = 9.5) obtained for the non MA-using group (n

=

1 7). This difference, however,

was not statistically significant [t( l 8. 1 ) = 1 .087, p = .29 1 ). Thus, null hypothesis # 1 failed
to be rejected for this scale. Hypothesis #2 was not substantiated for non-physical abuse,
as the mean score for MA users was 1 6.9 points below the clinical cutting score.
Hypothesis #3 was not supported for this scale as no significant correlation between
severity of craving and non-physical abuse was observed (rs = -. 1 1 6, p = .263).

Physical abuse - Surprisingly low problems were reported by each group for
problems with physical abuse. A mean physical-abuse score of 1 .4 (SD = 3 .6) was
obtained for the MA-using group (n = 1 5). This was 1 .4 points higher than the mean of
0.0 (SD = 0.0) obtained for the non MA-using group (n

=

1 7). This difference was not

statistically significant [t( l 4) = 1 .482, p = . 1 6 1 ). Thus, null hypothesis # 1 failed to be
rejected for this scale. Further, hypothesis #2 was rejected for physical abuse with the
mean score for MA users lying 28.6 points below the clinical cutting score. Hypothesis
#3 was also supported for this scale, with the Spearman's Rho test showing a significant
correlation between self-reported severity of craving and MPSI score for physical abuse
(rs .338, p = .029). Severity of cravings, thus, accounted for 1 1 .4% of the variance
=

observed for physical abuse.

Fearfulness - A mean fearfulness score of 20.4 (SD = 1 1 .9) was obtained for the
MA-using group (n

=

1 5). This was 1 2.0 points higher than the mean of 8.4 (SD = 8.3)

obtained for the non MA-using group (n = 1 7), indicating a statistically significant
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difference [t(30) = 3.320, p = .002). This allowed for a rejection of null hypothesis # 1 on
this scale. Hypothesis #2, however, was not substantiated for fearfulness, with the mean
score for MA users lying 9.6 points below the clinical cutting score. Hypothesis #3 was
also supported for this scale, with the Speannan's Rho test showing an extremely
significant correlation between self-reported severity of craving and MPSI score for
fearfulness (rs = .562, p = .000). Severity of cravings, thus, accounted for 3 1 .6% of the
variance observed for fearfulness.
Ideas of reference - A mean ideas-of-reference score of 25.0 (SD = 1 7.6) was
obtained for the MA-using group (n = 15). This was 20. 1 points higher than the mean of
4.9 (SD = 6. 7) obtained for the non MA-using group (n = 1 7), indicating a statistically
significant difference [t( l7.5) = 4. 163, p = .00 1 ). This allowed for a rejection of null
hypothesis #1 on this scale. Hypothesis #2, however, was not substantiated for MA users
on the fearfulness scale, with their mean score lying 5.0 points below the clinical cutting
score. Hypothesis #3 was also supported for this scale, with the Spearman's Rho test
showing an extremely significant correlation between self-reported severity of craving
and MPSI score for ideas of reference (rs = .752, p = .000). Severity of cravings, thus,
accounted for 56.6% of the variance observed for ideas of reference.
Phobias - A mean phobias score of 32.9 (SD = 14.6) was obtained for the MA
using group (n = 1 5). This was 1 6.3 points higher than the mean of 1 6.6 (SD = 1 1 .3)
obtained for the non MA-using group (n = 1 7), indicating a statistically significant
difference [t(30) = 3.558, p = .00 1 ). This allowed for a rejection of null hypothesis # 1 on
this scale. Though not hypothesized, the mean score for MA users fell 2.9 points above
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the clinical cutting score, indicating the presence of a si gnificant problem. Hypothesis #3
was also supported for this scale, with the Spearman's Rho test showing an extremely
si gnificant correlation between self-reported severity of craving and MPSI score for
phobias (rs = .58 1 , p = .000). Severity of cravings, thus, accounted for 33.8% of the
variance observed for phobias.
Guilt - A mean guilt score of 44.3 (SD = 1 9.5) was obtained for the MA-using

group (n = 1 5). This was 26 points higher than the mean of 1 8.3 (SD = 1 8.2) obtained for
the non MA-using group (n = 1 7), indicating a statistically significant difference [t(30) =
3.896, p = .00 1 ). This allowed for a rejection of null hypothesis # 1 on this scale.
Hypothesis #2 was also confirmed for guilt, with the mean score for MA users lying 1 4.3
points above the clinical cutting score, indicating the presence of a significant problem.
Hypothesis #3 was also supported for this scale, with the Spearman's Rho test showing
an extremely si gnificant correlation between self-reported severity of craving and MPSI
score for guilt (rs = .61 0, p = .000). Severity of cravings, thus, accounted for 37.2% of the
variance observed for guilt.
Work problems - A mean work-problems score of 27.2 (SD = 14.5) was obtained

for the MA-using group (n = 1 0). This was 6. 1 points higher than the mean of 2 1 . 1 (SD =
1 2. 1 ) obtained for the non MA-using group (n = 1 3). This difference, however, was not
statistically significant [1(2 1 ) = 1 .099, p = .284). Thus, null hypothesis # 1 failed to be
rejected for this scale. Further, hypothesis #2 was rejected for work problems with the
mean score for MA users falling 2.8 points below the clinical cutting score. Hypothesis
#3 was also supported for this scale, with the Spearman's Rho test showing a significant
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correlation between self-reported severity of craving and MPSI score for work problems
(rs = .407, p = .027). Severity of cravings, thus, accounted for 16.6% of the variance
observed for work problems.
Confused thinking - A mean confused-thinking score of 49.5 (SD = 23.3) was
obtained for the MA-using group (n = 15). This was 3 1 .0 points higher than the mean of
1 8.5 (SD = 1 7 .2) obtained for the non MA-using group (n = 17). This difference was
extremely significant [t(30) = 4.3 14, p = .000). This allowed for a rejection of null
hypothesis # 1 on this scale. Hypothesis #2 was also confirmed for confused thinking,
with the mean score for MA users lying 1 9.5 points above the clinical cutting score,
indicating the presence of a significant problem. Hypothesis #3 was also supported for
this scale, with the Spearman's Rho test showing an extremely significant correlation
between self-reported severity of craving and MPSI score for confused thinking (rs =
.654, p = .000). Severity of cravings, thus, accounted for 42.8% of the variance observed
for confused thinking.
Disturbed thinking - A mean disturbed-thinking score of 3 1 .6 (SD = 25. 1 ) was

obtained for the MA-using group (n = 15). This was 1 6.8 points higher than the mean of
14.8 (SD = 1 8.9) obtained for the non MA-using group (n = 17), indicating a statistically
significant difference [t(30) = 2. 1 54, p = .039). This allowed for a rejection of null
hypothesis # 1 on this scale. Hypothesis #2 was also confirmed for disturbed thinking,
with the mean score for MA users lying 1 .6 points above the clinical cutting score,
indicating the presence of a significant problem. Hypothesis #3 was also supported for
this scale, with the Spearman's Rho test showing a significant correlation between self-
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reported severity of craving and MPSI score for disturbed thinking (rs = .4 1 7, p = .009).
Severity of cravings, thus, accounted for 1 7.4% of the variance observed for disturbed
thinking.
Memory loss - A mean memory-loss score of 37. 1 (SD = 26.6) was obtained for

the MA-using group (n = 1 5). This was 24.2 points higher than the mean of 1 2.9 (SD =
1 0. 1 ) obtained for the non MA-using group (n = 1 7), indicating a statistically significant
difference [t( l 7.5) = 3 .334, p = .004). This allowed for a rejection of null hypothesis #1
on this scale. Hypothesis #2 was also confirmed for memory loss, with the mean score for
MA users lying 7 . 1 points above the clinical cutting score, indicating the presence of a
significant problem. Hypothesis #3 was also supported for this scale, with the Spearman's
Rho test showing a significant correlation between self-reported severity of craving and
MPSI score for memory loss (rs = .553, p = .00 1 ). Severity of cravings, thus, accounted
for 30.6% of the variance observed for memory loss.
A lcohol abuse - A mean alcohol-abuse score of 20.5 (SD = 27.6) was obtained for

the MA-using group (n = 1 5). This was 1 4.7 points higher than the mean of 5.8 (SD =
1 1 .2) obtained for the non MA-using group (n = 1 7). This difference, however, was not
statistically significant [t(l 8) = 1 .926, p = .07). Thus, null hypothesis # 1 failed to be
rejected for this scale. Hypothesis #2 was also rejected for alcohol abuse, with the mean
score for MA users falling 9.5 points below the clinical cutting score. Hypothesis #3 was
not supported for this scale as no significant correlation between severity of craving and
alcohol abuse was observed (rs = .070, p = .353).
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Drug abuse - A mean drug-abuse score of 69. 7 (SD = 26.5) was obtained for the
MA-using group (n = 15). This was 67.3 points higher than the mean of 2.4 (SD = 4.9)
obtained for the non MA-using group (n = 17). This difference was extremely significant
[t(14.8) = 9.712, p = .000). This allowed for a rejection of null hypothesis #1 on this
scale. Hypothesis #2 was also confirmed for drug abuse, with the mean score for MA
users lying 39.7 points above the clinical cutting score, indicating the presence of a
significant problem. Hypothesis #3 was also supported for this scale, with the Spearman' s
Rho test showing an extremely significant correlation between self-reported severity of
craving and MPSI score for drug abuse (rs = .865, p = .000). Severity of cravings, thus,
accounted for 74.8% of the variance observed for drug abuse.

69
Chapter 5: Discussion

Summary ofFindings
Table 7 summarizes the findings of this study in terms of which of the three
hypotheses were supported for each scale.
Hypothesis # 1 , that on each subscale, the MA-using group would report a mean
score higher than that of the non MA-using group, to a statistically significant degree,
was supported for the following scales: depression, partner problems, child problems,
neighbor problems, aggression, fearfulness, ideas of reference, phobias, guilt, confused
thinking, disturbed thinking, memory loss, and drug abuse. Hypothesis # 1 was not
supported for: self-esteem, sexual discord, mother problems, father problems, personal
stress, friend problems, school problems, work associates, family problems, suicide, non
physical abuse, physical abuse, work problems, and alcohol abuse.
Hypothesis #2, that the MA-using group would report mean scores which lay
above the clinical problem threshold for depression, self-esteem, child problems, personal
stress, aggression, suicide, non-physical abuse, physical abuse, fearfulness, ideas of
reference, guilt, work problems, confused thinking, disturbed thinking, memory loss,
alcohol abuse, and drug abuse, was supported for the following subscales: depression,
self-esteem, personal stress, aggression, guilt, confused thinking, disturbed thinking,
memory loss, and drug abuse. This hypothesis was not supported for child problems,
suicide, non-physical abuse, physical abuse, fearfulness, ideas of reference, work
problems, and alcohol abuse. However, there were additional areas to which hypothesis
#2 was not applied, but in which MA users' average scores fell at or above the clinical

70

Table 7
Summary ofHypotheses Supported
HyPOthesis
#1

#2

no
yes * *
no
no
no

yes
no
no
no
yes

Subscale

Sexual Discord*
Child Problems
Mother Problems
Father Problems

no
yes * *
no
no
yes

-��------�-��
yes

School Problems*
Aggres ·i on
Work Associates*
Family Problems
Suicide
Non-Physical Abuse
Physical Abuse
Fearfulness
Ideas of Reference
Phobias*
Guilt
Work Problems
Confused Th ink ing* _____
Disturbed hiTiking
Memory Loss
Alcohol Abuse
Drug Abuse

��--

ye --�-- �$
yes
no
no
no
no
no
no
no
no
yes
no
yes
no
xe
yes
yes
yes
yes
yes
no
no
yes
�es
no
yes
yes
ye
yes______;;__
no ------·no- �-----no_,
yes
yes
yes
no
no
no
no
no

------

___

Note. Hypothesis # I was that there would be a statistically significant difference
in MPSI score between groups. Hypothesis #2 was that MPSI scores for MA
users would exceed clinical cutting scores for certain MPSI subscales.
Hypothesis #3 was that severity of craving for MA would be positively correlated
with MPSI scores. Areas with all three hypotheses supported are shaded.
* = areas in which MA users exceeded clinical cutting scores that were not
predicted
* * = a reverse relationship was found
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cutting score. These areas were: partner problems, sexual discord, friend problems,
neighbor problems, school problems, work associates, and phobias. Finally, there were
several scales on which the non-MA using group 's scores fell above the clinical cutting
scores. These areas were: self-esteem, sexual discord, neighbor problems, family
problems, and school problems.
Hypothesis #3, that there would exist a positive correlation between severity of
craving for MA reported and score on the each of the 27 subscales of the MPSI, was
supported for the following scales: depression, partner problems, child problems,
personal stress, neighbor problems, aggression, physical abuse, fearfulness, ideas
reference, phobias, guilt, work problems, confused thinking, disturbed thinking, memory
loss, and drug abuse. Thus, this hypothesis was not supported for: self-esteem, sexual
discord, mother problems, father problems, friend problems, school problems, work
associates, family problems, suicide, non-physical abuse, and alcohol abuse.
Interpretation of Results

In order to integrate the findings associated with the three questions asked by this
study, it seems most useful to begin by examining areas in which significance was
obtained in all three areas. The areas for which MA users differed significantly from non
users, exceeded clinical cutting scores, and on which craving for MA had a significant
effect were: depression, partner problems, neighbor problems, aggression, phobias, guilt,
confused thinking, disturbed thinking, memory loss, and drug abuse. These are all life
areas on which MA itself has the strongest effect. These areas are discussed in order of
the magnitude of the problem as measured by the clinical cutting scores of the MPSI.
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Areas in which significance was obtained on one or two of the research questions are
addressed next. Finally, areas in which no significant results were obtained are discussed.
Areas that did not show support for all three hypotheses are discussed in no particular
order.
A reas with all three hypotheses supported.
Drug abuse - The area in which MA users exceeded the clinical problem
threshold by the greatest amount was drug abuse. This finding is logically congruent with
the fact that these individuals are using a drug which, as previous research has noted,
carries with it many problems and complications. The construct of drug abuse as assessed
on the MPSI relates to issues surrounding reason for use, situations in which use is likely
to occur, and consequences associated with use. The findings in this area are intuitive and
no alternative explanations or implications for them are speculated.
Neighbor problems - The next area associated with the most severe elevation of
MPSI score was neighbor pro�lems. As the MPSI conceptualizes these problems, they
are exclusively relational issues such as liking neighbors and being liked by them and
desire to be part of the neighborhood, versus a different neighborhood. To the
researcher's knowledge, this is an original finding which does not relate specifically to
any existing research. Possible reasons for relational problems that MA users experience
with their neighbors are many and variegated. It should first be noted, that MA use can
often be quite easy to detect as a result of the distinctive aroma (assuming that it is
smoked or cooked), the physical effects, and the erratic and often paranoid behavior of
the user. Thus, a user may be looked down upon in his or her neighborhood simply due to
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the stigma associated with drug use. The behavior of a MA user may also appear strange
or dangerous to non-using neighbors resulting in avoidance. In addition, paranoia,
irritability, and aggression may result in incidents in which fights or arguments with
neighbors arise. The disturbed sleep patterns of MA users may also cause conflict with
neighbors as a result of the individual's being active at all hours of the night, potentially
disturbing the sleep of others. Finally, it is noted that a clinically significant score in this
area was also obtained for the non-MA using group. This finding suggests
reconsideration of the norming of this scale with the population at large or examination of
the cause of severe neighbor problems in a "normal," non-MA using population. As
speculation for the elevated scores of non users, the stresses and disruptions associated
with dorm and "college apartment" style living may be to blame. Clinically, the findings
for MA users in this area beg clinicians to be aware of environmental issues which may
influence or exacerbate use and which may be obstacles to an individual's successful
reintegration to the community following incarceration.
Partner problems - The partner-problems subscale of the MPSI assesses

perceived quality and status of the respondent's relationship (presumably, a romantic
one). Although no previous research has addressed the issue of partner-relationship
problems specifically, information has been generated which can help to explain MA
users' elevated scores in this area. For example, it was cited previously that the
occurrence of interpersonal violence is an extremely common characteristic of the lives
of MA users (Pach & Gorman, 2002; Cohen, Dickow, Homer, Zweben, Balabis,
Vandersloot, & Reiber, 2003). In addition, increased number of sexual partners (Molitor,
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Truax, Ruiz, & Sun, 1998; Pach & Gorman, 2002) and increased risk of transmission of
sexually transmitted diseases (Shoptaw, Reback, & Freese, 2002; Peck, Shoptaw,
Rotherman-Fuller, Reback, & Bierman, 2005) are also common correlates of MA use.
Paranoia associated with MA use may also contribute to disharmony with one's partner.
Finally, the fact that MA users' scores for sexual discord fell, on average, above the
clinical cutting score, is likely another contributor to problems with partners. However, it
is also noted that the process of list-wise deletion caused sample size for users to be
greatly reduced on this scale. The finding that MA users were less likely to have a
partner, to be currently sexually active, and that 87% of them were not married, is itself
significant. The information collected in this area has implications similar to those cited
above in regard to neighbor problems. A highly unhappy or tempestuous relationship
could easily become a trigger for use or relapse. In addition, problems in this area may be
exacerbating depression, self-esteem, aggression, or physical/non-physical abuse. Thus,
partner relationships seem to be a key area for focus during initial assessment, as well as
for continued monitoring.
Confused thinking - Confused thinking is an area in which the elevated scores

observed in this study came as no surprise. The questions on this subscale seem to
address confusion itself, mental organization, and impaired cognition. As was cited
previously, impaired cognition is a known correlate of MA use (Iwanami, Kanamori,
Suga, Kaneko, & Kamijima, 1995; Rogers, Everitt, Baldacchino, Blackshaw, Swainson,
Wynne, Baker, Hunter, Carthy, Booker, London, Deakin, Sahakian, & Robbins, 1999;
Simon, Dornier, Carnell, Brethen, Rawson, & Ling, 2000; Salo, Nordahl, Possin,
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Leamon, Gibson, Galloway, Flynn, Henik, Pfefferbaum, & Sullivan, 2002). In addition,
such symptoms are typical of the disorganization of thought associated with psychosis, a
near inevitability for chronic MA users (Ellinwood, 1 969; Sekine, Iyo, Ouchi,
Matsunaga, Tsukada, Okada, Yoshikawa, Futatsubashi, Takei, & Mori, 2001 ; R. Rawson,
personal communication, March 20, 2006). MA's effects on neurochemistry in the neo
cortex (Eisch & Marshall, 1 998; Deng, Ladenheim, Tsao, & Cadet, 1 999; Stumm,
Schlegel, Schafer, Wurz, Mennel, Krieg, & Vedder, 1 999; Volkaw, Change, Wang,
Fowler, Franceschi, Sedler, Gatley, Hitzemann, Ding, Wong, & Logan, 200 1 ) may
account for some of this confusion. No alternative explanations are ventured for the
elevated scores in this area. Clinically, these results identify a barrier to nearly any
modality of treatment. A person who cannot organize their thoughts or trust their own
perceptions is not likely to fully understand what is being told to them by a counselor. It
may be more helpful then to avoid cognitive behavioral (and other similarly mentally
demanding techniques) in favor of less complex therapies which employ very simple
concepts and appeal to a person on an intuitive, spiritual, or emotional level, rather than a
rational one. This may assist in delaying relapse until a person's cognitive faculties begin
to return to them.
Guilt - The guilt subscale is focused on personal shame, internal attributions for

things that have gone wrong, and regret/remorse for previous behavior. The researcher is
not aware of any previous research which has correlated MA use with severe feelings of
guilt. It is speculated that because individuals trapped in their addition to MA often do
things (such as lie, steal, and abuse) which they would have, before onset of dependence,
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found morally reprehensible, a strong sense of regret and guilt is predictable. The fact
that some of these feelings may be internalized helps to explain elevated problem scores
for depression and self-esteem. It may be productive to these individuals for their
counselors to assist them in re-attributing some of these behaviors to the drug itself, their
addiction, or the situations in which the drug's grip landed them.
Depression - The finding that depression is a significant problem for recovering

MA users falls right in line with previous research (Kalechstein, Newton, Longshore,
Anglin, van Gorp, & Gawin, 2000; Peck, Shoptaw, Rotherman-Fuller, Reback, &
Bierman, 2005). Based on neuropsychological research, this effects seems clearly
attributable to neurochemical mechanisms associated with MA use which have been
solidly established (Kogan, Nichols, & Gibb, 1 976; Wagner, Seiden, & Schuster, 1 979;
Wagner, Ricaurte, Seiden, Schuster, Miller, & Westly, 1 980; Fuller & Hemrick-Luecke,
1 980; Ricaurte, Guillery, Seiden, Schuster, & Moore, 1 982; Gibb, Johnson, & Hanson,
1 990; Robinson, Yew, Paulson, & Camp, 1 990; Itzhak, Gandia, Huang, & Ali, 1 996; R.
Rawson, personal communication, March 20, 2006). Of course, one alternative
explanation for the results in this areas obtained in the current study is that the depression
observed is situational, rather than MA-use related. For example, the individuals in the
MA-using group were necessarily in residential treatment, restricted by such things as
curfews and level systems. These individuals were also, almost universally, recently
released from prison. Any number of complications, disappointments, and stresses
associated with this status may have contributed to elevated scores for depression.
Clinically, the findings obtained in this area identify a potentially severe obstacle to
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treatment. As depressed mood may be a precipitant, as well as a result of, MA use, a
continually perpetuating cycle is in place. A person often chooses to use, or relapses, in
order to feel better and as a result, they feel worse. Thus, psychiatrists and counselors
must be prepared to address depression as a prerequisite for treating the addiction.
Memory loss - As assessed by the MPSI, elevated scores on this scale seem to

indicate impairment in working memory, as opposed to amnesia. The questions asked
probe a number of different areas in which such impairment may be a nuisance or a more
serious problem. Conflicting evidence exists in the literature regarding MA' s effects on
memory performance. Thompson, Hayashi, Simon, Geaga, Hong, Sui, Lee, Toga, Ling,
and London (2004) found hippocampal damage and detrimental effects on recall in MA
users. The evidence obtained in the current study, though limited by the self-report nature
of the data, appear to support the conclusions of these authors. Mewaldt and Ghoneim
( 1 979), however, found that acute administration of MA can actually improve
performance on recall tasks. Memory loss observed in the current study may relate to
hippocampal damage cited above, or the sustained state of intoxication in which MA
users frequently remain for several days/weeks. Kalechstein, Newton, and Green (2003)
found that impairment in memory function is very common among MA users, especially
as they begin their recovery. Perhaps then, withdrawal of the memory stimulating
properties of the drug leaves the users with neurochemical deficits which render memory
tasks more difficult. It is also possible that sustained use itself accounts for the
impairment observed. Though clinical implications of this finding may be superficial
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(such as the clients' ability to keep track of therapy sessions, therapy homework, work
schedules, etc.), the finding itself is important.
Phobias - Perhaps one of the most surprising findings of this study was the

clinically significant mean score of MA users for phobias. This finding is, however
consistent with the paranoid ideation associated with MA-induced psychosis. Although a
small amount of research has correlated AP use with social phobia (e.g. Bristol, 2000),
little has shown a strong connection in this area, and none (to the researcher' s
knowledge) has identified other specific phobias as a concern for MA users. The fact that
MA is often used as a social lubricant helps to explain how social phobia might tie into
the topic at hand. However, the construct of phobia on the MPSI is quite broad and
clearly intends to assess the presence of a number of different specific phobias. It does
not seem that symptoms of social phobia alone would account for such elevated scores as
were observed. In looking at the scores of individual users, the researcher noted that
questions on which MA users reported significant fears were not exclusive to social
phobias and included claustrophobia (small spaces), aviophobia (flying), xenophobia
(strangers), isolophobia (being alone), agoraphobia (open spaces), asthenophobia
(fainting), etc. Beyond the paranoia associated with MA psychosis (Ellinwood, 1 969;
Sekine, Iyo, Ouchi, Matsunaga, Tsukada, Okada, Yoshikawa, Futatsubashi, Takei, &
Mori, 2001 ; R. Rawson, personal communication, March 20, 2006), which may help to
explain some of these phenomena, no other explanation is currently postulated. The
clinical implications in this area will vary depending on what type(s) of phobia(s) the
client is reporting. However, it seems in general that treatment aimed at the reduction of
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anxiety may help these individuals to avoid seeking out MA as a type of escape behavior
and may lubricate the recovery process for certain people.
Disturbed thinking - The MPSI scale for disturbing thoughts specifically assesses

the extent to which a person's own thoughts are unsettling to them, as well as the
persistence of these thoughts. To the author's knowledge, no previous study has produced
data on MA' s effects on this area. However, given the paranoid psychosis which
frequently results from MA dependence (Ellinwood, 1 969; Sekine, Iyo, Ouchi,
Matsunaga, Tsukada, Okada, Yoshikawa, Futatsubashi, Takei, & Mori, 2001 ; R. Rawson,
personal communication, March 20, 2006), it is not surprising that users had a clinically
significant score in this area. The reports and poetry of MA users describe the drug as
something of a demon, putting thoughts in their heads and making them do things that
would never have done otherwise. Clinically, the findings in this area urge practitioners
to be vigilant in their assessment of psychosis with MA users. In addition, newly
abstinent MA users may require treatment which resembles that of schizophrenia more
closely than that of traditional addictions counseling.
Aggression - The MPSI construct of aggression consists of questions about

aggressive interactional style and intimidation, as well as physical violence itself. As
increased incidence of interpersonal violence is a common correlate of MA use (Pach &
Gorman, 2002; Cohen, Dickow, Homer, Zweben, Balabis, Vandersloot, & Reiber, 2003),
the clinically significant scores recorded in this area are not surprising. However, it is
possible that aggression is a preexisting condition which tends to lead to "self
medication" type use of MA, rather than a result of use. Regardless of which preceded
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· the other, the presence of elevated aggression is a condition which will likely cause an
individual to either end up hurt, or in prison . Of course, less severe consequences of
aggression are also likely to occur such as alienation of friends, family, and others, and
job loss. Thus, it is of utmost importance that this symptom be addressed in treatment.
Helping these individuals to learn assertive coping mechanisms will lead to better
outcomes across life domains in the lon g run .

Areas with two hypotheses supported.
Childproblems - This area is one which quite startling, and completely
unexpected, findings were obtained. Although neither test group exceeded the clinical
cutting score for this scale, it was found that a statistically significant difference between
groups existed in the opposite direction of that expected. This means that individuals not
using MA were found to have more problems with their relationships with their children
than MA users. There are several plausible explanations for this findin g. First, as this was
a variable for which list-wise deletion was used to address missin g data, sample size for
its analysis was greatly reduced (nma users

=

8; nnon-ma users

=

4). Thus, confidence in

applying this fin din g to any population (MA-using or otherwise) is very low. Secondly, it
could be the case that individuals who skipped this subscale were in fact saying "I have
no problems with my kids," rather than "I have no kids," the latter of which was the
statistical assumption . However, given the mean age of 23 .65 for this group, and the fact
that 7 1 % of control group participants were sin gle, it seems unlikely that this was the
case. When the I-test was conducted on this variable with "O's" being inserted in cases for
which the scale was skipped, however, the means of the two groups were much closer
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(Mma users = 4.9, Mnon-ma users = 6 .0), and much further from the clinical cutting score,
especially in the case of non-users. It was also observed for this scale, through the
Spearman rank-order correlation test, that severity of craving was negatively correlated
with child problems to a significant degree. This, however, was contingent upon the
observed means and this effect disappeared when, as was done above, "O's" were
substituted for missing scores. It was also surprising, however, how few problems with
children were reported by MA users, given the research on the topic. This likely relates,
however, to the fact that the MPSI construct of child problems is focused on perception
of, or attitude towards, the relationship with the child as opposed to more interactional
issues like abuse, neglect, or the child's behavior. An interesting follow-up study might
survey children of MA users in regard to problems with their parents. As it is the
researcher's opinion that the inverted findings on this scale do not accurately represent
the reality of the situation, no clinical implications are drawn from them.
Personal stress - It was also surprising that hypothesis # 1 was not supported for
personal stress. The finding on hypothesis #2 was, however, indicated that MA users are
in fact having significant problems in this area. This is consistent with the stressful
lifestyle maintained by many MA users, as well as anxiety which has been identified by
previous research (Peck, Shoptaw, Rotherman-Fuller, Reback, & Bierman, 2005). The
questions on this subscale relate mostly to a feeling of being on the verge of losing
control or having a "breakdown." The reason that the between-groups difference was not
substantially significant was that, once again, scores for the non-MA using group were
also elevated. The clinical problem threshold was not surpassed for non users, but it was
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closely approached. Although it seems reasonable that undergraduate students would
report elevated stress relating to their studies, etc., for such a magnitude of stress to
average out to near-significance across 1 7 non-MA using individuals draws into question
the norming of this scale in regard to the general population. The clinical implications of
this finding may be pharmacological, indicating that an anxiolytic medication may be
appropriate for these individuals. In addition, the teaching of life skills, such as
organization and scheduling, as well as relaxation techniques may be helpful as these
individuals go through treatment. The reduction of anxiety and stress may help
individuals in recovery to avoid using as an escape behavior.
Fearfulness - For the fearfulness scale, MA users' scores differed significantly

from non users' , and were found to be significantly correlated with severity of craving.
This construct on the MPSI refers to irrational, non-specific fears and their impact on
functioning. There is no research known to the author which has identified fearfulness as
a correlated of MA use. This fear may relate to the paranoia associated with MA
psychosis (Ellinwood, 1 969; Sekine, Iyo, Ouchi, Matsunaga, Tsukada, Okada,
Yoshikawa, Futatsubashi, Takei, & Mori, 200 I ; R. Rawson, personal communication,
March 20, 2006). MA users did not exceed the clinical problem threshold and, in fact, fell
short of it by 1 0 points. This tells us that MA users are having significantly more free
floating fear than non users (especially when cravings are more intense), but not to a
degree that it is severely interfering with functioning. The implication of this finding is
that clinicians need to be aware of the potential for problems in this area, but not overly
focused on it. Also implied is the importance of building a therapeutic relationship

83

characterized by trust with these individuals in order to provide reassurance of their
safety.
Ideas ofreference - It was found that for this subscale, MA users' scores were

significantly higher than non users', and that they were strongly influenced by severity of
craving. MA users, however, fell short of the clinical cutting score by 5 points on
average. This scale assesses the degree to which the respondent feels that other people
are talking about them, focused on them, or "out to get them" in some way. Given the
frequent onset of paranoid psychosis in MA users (Ellinwood, 1 969; Sekine, Iyo, Ouchi,
Matsunaga, Tsukada, Okada, Yoshikawa, Futatsubashi, Takei, & Mori, 200 1 ; R. Rawson,
personal communication, March 20, 2006), it is not surprising that users showed elevated
scores for these types of delusions. Non users, as would be expected, reported very low
scores in this area. The fact that the MA users in this study were in recovery for some
period of time, allowing time for the acute psychosis to begin to decline, may explain
why scores obtained were not above the cutting score. However, given the near
significance of the scores, clinicians certainly need to be assessing this area thoroughly at
intake. This is also, once again, an indication that psychiatric symptoms may need to be
stabilized before any progress in treatment of the addiction can be made.
Areas with only one hypothesis supported.
Self-esteem - For the self-esteem subscale, only hypothesis #2 received support.

This scale assesses the individuals' perception of themselves, as well as their impression
of others' perceptions of them. Though no research, to the author' s knowledge, has
addressed the self-esteem of MA users, such a finding is consistent with literature on the
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prevalence of depression in this population (Kalechstein, Newton, Longshore, Anglin,
van Gorp, & Gawin, 2000; Peck, Shoptaw, Rotherman-Fuller, Reback, & Bierman,
2005). It is also intuitive based on the extreme decline of physical appearance
experienced by many MA users, as well as the finding that significant guilt and shame is
often a problem for users. Perhaps the most notable finding in this area was the fact that
the mean score for non-MA users' also fell above the clinical cutting score. This likely
explains why hypothesis # I was not supported in this area. Had the control group
exhibited more normative levels of self-esteem, the difference between groups would
have been more dramatic. However, barring some unknown variable in the control group
which accounted for the clinically significant self-esteem problems observed, this
finding, once again, brings into question the norming of this scale in regard to the general
population. For MA users, the findings on self-esteem urge clinicians address issues
underlying drug use in addition to the addiction itself. People that do not like themselves,
are unlikely to show concern for their own physical safety and health. It is also another
example of a continually perpetuating cycle in which a person may use in order to feel
better about him or herself and, as a result, lose the ability to feel good about anything.
Sexual discord - Findings in this area were significant only concerning hypothesis

#2, in regard to clinical cutting scores. However, it was interesting that both groups'
mean scores fell above the cutting score for this scale. This subscale is aimed at assessing
respondents' perceptions of the quality of their sex life, as well as their impressions of
their partners' perceptions thereof. It was not hypothesized that MA users would report
significant problems in this area due to the findings of previous research which indicate
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sexually enhancing properties of the drug (e.g. Gorman, Clark, Nelson, Applegate,
Amato, & Scrol, 2003). Other than anecdotal reports (Associated Press, 2004), the author
is not aware of any empirical research which has indicated sexual dysfunction as an
outcome of sustained use. However, it is perhaps more concerning that undergraduate
social work students are having, on average, clinically significant dissatisfaction with
their sex lives. This scale was one for which sample size was greatly reduced for MA
users (presumably due to lack of current sexual activity; n = 5), but not significantly for
non users (n = 1 3 ). Thus, this finding for non users may hold true when applied to a
larger undergraduate population. This issue begs further research and, once again, draws
into question the norming of the MPSI on this scale. No clinical implications are derived
from these findings.
Friend problems - For this subscale, the only significant finding was that MA

users' mean score fell just above the clinical cutting score. This scale assesses the
individual's attitude toward their friends, as well as the quality of relationship with those
friends. No previous research has addressed this area. The problems observed in this area
could be viewed as precipitants of MA use for its social lubricating properties. However,
it seems more likely that they represent an alienation of friends that has occurred as a
result of use, for any number of reasons. Clinically, this finding indicates the need to

assess, and to help develop, adequate social support for individuals in recovery. It is also
important to assess the influence that MA-using friends are having upon the client's use
and help the individual to remove him or herself from social situations which are likely to
trigger relapse.
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School problems - This was yet another area in which interesting findings for the

control group were obtained as well as for the experimental group. This scale is directed
toward the individual's attitude toward school content, the experience of school in
general, and his or her own performance at school. Though no previous research was
identified which evaluated MA users regarding school problems, it is intuitive based on
cognitive deficits, poor sleep habits, and psychosis that they would report significant
problems in this area. Although sample size was greatly reduced for MA users on this
scale (presumably because they were not attending school; n = 5), the amount by which
they exceeded the cutting score (16.1 points) was significant. Also significant, however,
was the fact that non users also exceeded the problem threshold (though only by .9
points). Had more "normative" levels of school problems been found in the control
group, the MA-using group's scores would likely have supported hypothesis #1 . This
scale is yet another for which norming is brought into question by the results obtained. If
1 7 "randomly" selected students report clinically significant scores on school problems,
what is considered a "normal" amount of problems with school? Implications for the
findings regarding MA users on this scale involve connecting individuals interested in
pursuing education with resources which will assist them in developing effective study
habits, with the goal of improving attitude and performance in school.
Work associates - The only significant finding for the problems with work

associates scale was a mean score for MA users which was above the clinical problem
threshold. This scale assessed the individual' s relationships with coworkers. Though no
previous research has addressed this area, and no hypothesis was made for it, this finding

87

is somewhat intuitive given the relational problems which appear to run through the lives
of MA users. This finding has implications for transitioning clients in treatment back into
the workplace. These individuals needs assistance in developing social skills which will
allow them to get along with coworkers to a degree sufficient to keep them employed.
Family problems - The family problems scale was another in which unexpected,
and counterintuitive, findings were obtained. It seems that in this area, MA users actually
reported.fewer problems than the control group, though not to a statistically significant
degree. The non users mean score, however, did in fact exceed the clinical cutting score.
The method of handling missing data made very little difference in this case. When "O's"
were substituted for missing data, rather than employing list-wise deletion, the mean for
non users was unchanged, and that of MA users was only increased by one point (though
that did cause MA users to exceed the clinical cutting score). The near-significant mean
score obtained for MA users is intuitive based on alienation of family members as a result
of relational problems, as well as potentially hurtful or damaging behaviors, associated
with MA dependence. The finding regarding the non-MA using group has implications
regarding the norming of this scale, as there does not seem to be any systematic reason
why these individuals should be reporting clinically significant family problems. For MA
users, this finding once again urges clinicians to assist these individuals in developing a
level of social support and nurturance sufficient to help them through their recovery.
Work problems - The work problems scale was the only one for which correlation
between severity of craving and MPSI score was the only significant finding. Neither
group exceeded the clinical cutting score and the difference between groups was not
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statistically significant. This subscale addresses the individual's attitude toward their job
and workplace environment, especially their supervisor. Though the only research in this
area refers to the increased incidence ofjob loss among MA users (Morgan & Beck,
1 997; Pach & Gorman, 2002), it is intuitive that more severe cravings would result in
greater problems at work. This finding tells us that as recovery progresses and cravings
become less severe, these individuals are likely to report an improved attitude toward
their work environment. Clinicians can use this information to assist recovering MA
addicts in learning strategies for controlling, or handling appropriately, their cravings
(and the behavioral symptoms associated with them) while at work.
Areas in which no hypotheses were supported.
Mother andfather problems - It is notable that non-MA users averaged four

points higher than users on each of these scales. However, as the clinical cutting scores
were not exceeded and statistical significance in between-groups differences in means
was not reached, no meaning is read into this finding.
Suicide - Although it was hypothesized that MA users would exceed the clinical

cutting score in this area, it is, in retrospect, logical that such a finding was not obtained.
This is because, more than likely, individuals that entered the treatment center reporting
active suicidal ideation would have been identified at intake and placed into a more
intensive or restrictive program than the ones from which users were surveyed. The mean
score obtained for users was not significantly higher than that of non users and severity of
craving for MA did not appear to impact suicidality.
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Physical and non-physical abuse- Given the research on the prevalence of
interpersonal violence among MA users (Pach & Gorman, 2002; Cohen, Dickow, Homer,
Zweben, Balabis, Vandersloot, & Reiber, 2003), and the finding of the present study of
elevated levels of aggression among users, it is quite surprising that such low numbers
were obtained in these areas. However, there may be a logical explanation for why these
numbers may have been underrepresented in this population. Both of these subscales
refer to abuse originating with the person's partner. Very few of the MA users, it is
assumed, currently had partners. This statement is based on the fact that 87% of users
were either single or divorced, and the fact that only six people (out of 1 5) felt that the
partner problems scale was applicable to them. Thus, a user who skipped the physical
and non-physical abuse scales may have been saying, "I don't have a partner," rather than
"I don't experience abuse from my partner." When list-wise deletion was used in place of
substitution of "O's," the mean score for non-physical abuse exceeded the cutting score
and the mean for physical abuse was increased by 8.6 points. Thus, it seems plausible that
for MA-using individuals that did have a partner, non-physical abuse may have been a
significant problem. Also notable on these scales is the fact that the lowest score possible,
a "O," was obtained for physical abuse among non users. This indicates that not a single
individual in the control group reported the slightest problem in this area.
Alcohol abuse - The subscale for alcohol abuse also returned no significant
findings. However, the low incidence of consumption of alcohol observed (33.3% of MA
users, 2% less than that of non users), and the subthreshold MPSI score for this scale DO
fit in with the findings of other research (Huber, Ling, Shoptaw, Gulati, Brethren, and
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Rawson, 1 997; Peck, Shoptaw, Rotherman-Fuller, Reback, and Bierman, 2005).
However, had equal variances been assumed for the t-test on alcohol abuse, MA users
would have been shown to have significantly more problems in this area than non users
(p = .053 ).
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Chapter 6: Conclusions, Limitations, and
Recommendations for Further Research
Conclusion
Methamphetamine is a devastating drug which has taken the nation by storm, and
for which the myriad disastrous effects are still being uncovered. This study is evidence
that, despite the vast amount of research which has examined this substance over the past
30-or-so years, there is still much which is unknown. The "umbrella" question stated in
the purpose section which inspired and directed all of the complex methodology
employed, was, "what influence does MA use exert on psychosocial functionality?" The
short answer to this question is, "a significant amount of influence." The areas in which
MA' s effects were demonstrated most strongly by: ( 1 ) mean scores for users differing
significantly from non users; (2) mean scores exceeding clinical cutting scores; and (3)
showing covariance with severity of craving for MA, were: depression, partner problems,
neighbor problems, aggression, phobias, guilt, confused thinking, disturbed thinking,
memory loss, and drug abuse. In addition, however, MA users either differed
significantly from non users or exceeded the clinical problem threshold (the two main
concerns of this study), or both, on 20 of the 27 subscales of the MPSI. Furthermore,
several of the seven areas in which no significant results were obtained, were close
enough to significance to warrant further investigation into the topic. As for the tertiary
question of this study regarding the correlation of severity of craving for MA and
psychosocial functionality, significance was attained on 1 6 of the 27 subscales.
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Although many of the findings of the current study concur with previous research,
and none seem to contradict it, there were also areas of concern for MA users discovered
which have not yet been specifically identified or explored by previous research. Some of
these areas, however, could be predicted based on previous research, such as relational
problems (with friends, coworkers, neighbors, and partners), school problems, and work
problems. Others such as guilt, phobias, and sexual discord, however, appear to represent
unique findings. In addition, some of the findings regarding the control group and the
MPSI itself may prove to be useful in directing future research on the topic. The
limitations of the current study, as well as some of the areas identified which require
replication and further exploration, are discussed below.
Limitations

Although the limitations of this study were many, they do not necessarily degrade
the validity of the results obtained. They do, however, beg caution in their interpretation.
Perhaps the most limiting, though unavoidable, factor was the inability to isolate the
independent variable. 80% of subjects in the MA-using group were also regularly using
substances other than MA. This means that it is impossible to attribute as much of the
variance observed to MA alone as would have been possible with individuals exclusively
using MA. To compound this limitation, 52.9% of the control group was ALSO regularly
using some substance. As there is no way to "subtract" the effects of these substances
from the results obtained, we were actually comparing MA users to a group which may
be experiencing psychosocial problems of their own related to the use of these other
drugs. However, it can be assumed that the occurrence of substance use observed in the
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control group closely resembles that which would be found in any population of
undergraduate college students. In addition, the non-MA using group also reported
significant "pathology" on several of the MPSI' s subscales, as indicated by mean scores
which exceeded the clinical problem threshold. This effect narrowed the contrast between
MA users scores and what may have been observed in a group with more normally
distributed problems.
The disparity of certain traits between the two groups surveyed also seems to be
something of a limitation. First, mean age for the two groups was disparate by nearly 1 0
years. Secondly, there was a great amount of contrast between groups regarding gender
(MA users were 60% male, non users were 1 00% female) and race (MA users were 1 00%
Caucasian, non users were less than 60% Caucasian). Substantial differences also existed
in marital status, with MA users being MUCH more likely to be divorced/separated than
non users. Thirdly, there are inherent "subcultural" differences between a population of
post-incarceration recovering drug users and one made up of individuals who have
chosen to ( and were financially able to) pursue secondary education. Although these
specific differences were not examined and are thus not speculated upon, they do seem
intuitive as well as noteworthy. Fourth, it is also unknown, as explained previously, what
differences in socioeconomic status existed between the two groups. Given well
established information on the effects of poverty on any number of variables, this
information would have been quite useful. Finally, in a more ideal version of this study,
MA users would have been compared with several groups made up of users of drugs
other than MA. This is because certain problems observed may be correlated with drug
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abuse and dependence in general and may not be specific to MA. It would have been
more enlightening (though vastly more complex) to compare the effects of dependence
on MA with dependence on crack cocaine, for example, or heroin. All of the above
mentioned factors introduced the potential influence of variables extraneous to the
desired independent variable, MA use.
Another constraint on the generalizability of these results was small sample size.
As a result of difficulties in finding and gaining access to MA users in the Knoxville area,
a sample of 15 users for each group became the goal. It was heard over and over again in
the quest to find participants for the experimental group "MA hasn 't really entered the
urban areas of East Tennessee yet; crack cocaine is still !he main drug of concern here."
To exacerbate the problem of sample size, many cases had to be dropped through the
process of list-wise deletion as a result of missing data. Although doing so was the
method which made the most sense on variables (such as sexual discord) which had the
potential of being inapplicable to certain individuals, this practice DID result in several
(four) subscales for which n was below 1 0 for MA users. This had much smaller of an
effect on sample size for the control group, for which nearly all scales were either
complete or able to be inferred. It is also noted that the necessity of making such
inferences (e.g. - assigning zeroes to individuals who skipped certain scales which
seemed to indicate that the scale did not apply to them due to lack of the trait in question,
like depression) is also a limitation of this study. It seems, however, that few studies are
conducted which do not require some kind of statistical "guesswork" be done. It is
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maintained that the inferences made were logical and had little effect on the overall
results.
The final limitation of this study which must be mentioned relates to the design of
the demographic information sheet and the MA-use questionnaire. First, a certain amount
of "unnecessary" information was generated which was not used in the analyses
conducted. This information includes: number of members in household, occupation,
average combined household income, frequency of MA use within the past 30 days,
frequency of cravings for MA, and frequency of use of substances other than MA.
Secondly, and more importantly, was the exclusion of several questions which would
have been invaluable to the analyses conducted. No question was asked which assessed
the duration of MA use or the duration of abstinence from use. Given that much of the
current research on MA use is written in terms of duration of use, the former variable
would have lubricated the placement and analysis of this study amongst other similar
research. The latter question would have allowed for analysis of the effects of sustained
abstinence on the abatement of psychosocial difficulties. In addition, no information
about route of administration was obtained. Questions in this area were originally
included, but were removed due to the potential for introducing a user to a method of
taking the drug with which he or she was previously unfamiliar. Given the differences
cited earlier in the physiological and psychophysical effects associated with smoking
crystal MA versus injecting the drug or snorting the low purity powder, such information
would have allowed for interesting analysis of the degree to which such differences are
transferred into the psychosocial realm.

96

Recommendations for Further Research

First, a full replication of this study is recommended to ensure the accuracy and
generalizability of the findings. In doing this, it is recommended that stricter controls are
placed on extraneous variables (such as gender ratio, income, pathology, substance use,
etc.) for each group, in order to allow for greater isolation of the independent variable in
question. In future replications, it is recommended that special attention be paid to the
areas in which differences have been identified in the present study that have not been
shown or implied by previous research. These areas were sexual discord, feelings of guilt,
and phobias. Investigation into the etiology of the guilt and phobias observed is also
needed. It is also recommended that a similar study be conducted with the control group
being replaced by users of other drugs such as AP, crack, cocaine, and heroin. This will
allow for even further isolation of MA' s effects as they compare with those of other
drugs.
The number and magnitude of problems reported by members of the control
group in this study were astonishing. Areas in which control group members exceeded
clinical cutting scores were neighbor problems, family problems, self-esteem, sexual
discord, and school problems. In addition, there were areas in which non users did not
exceed, but closely approached (exceeded 25), clinical cutting scores. These areas require
further investigation and include: personal stress, parent problems, depression, and friend
problems. Further research is needed to confirm the presence of these problems, as well
as to investigate their etiology. Inquiry as to whether the results obtained are attributable
to a random anomaly of the sample, the influence of substance use in the sample,
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characteristic of the larger population, or a miscalculation in the setting of clinical cutting
scores on the MPSI, is needed.
It was very surprising in this study that such low scores were reported by MA
users for child problems. As this finding does not, based on previous research, seem to
accurately represent the difficulties MA users experience with their children, further
investigation is recommended. It is also recommended that research in this area be
conducted from the perspective of the child. Similarly, the lack of problems noted for
physical and non-physical abuse were unexpected and may require further investigation.
Finally, the literature on suicidality of MA users seems to be rather inconclusive.
Although the findings of the present study do not indicate severe problems with suicidal
ideation, anecdotal evidence (as well as some research) seems to suggest that successful
suicides are common among MA users. Further investigation into this area is advised.
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Appendix A
Methamphetamine-Use Questionnaire
*PLEASE CIRCLE OR FILL IN THE BEST RESPONSE
1 . Have you ever used methamphetamine in any form?
No

Yes

2. If yes, have you used methamphetamine within the last year?
Yes

No

3 . If yes, have you used methamphetamine within the last 30 days?
No

Yes

4. If yes, approximately how many times have you used methamphetamine within the last
3 0 days? _______ times
5 . If you use methamphetamine regularly, approximately how often do you use?
A. several times per year

D. once per week

B. once per month

E. several times per week

C. several times per month

F. daily

6. Do you experience cravings for methamphetamine?
Yes

No

7. If yes, describe your cravings using the following sca�e:
I
virtually
no cravmg

2
cravmg 1s
easily ignored

3
moderate
cravmg

4
severe/persistent
cravmg

5
uncontrollable
cravmg

125

8. If you answered yes to question #5, how often do you experience these cravings?
1
almost never

at least once
per month

at least once
per week

4
daily

5
constantly

9. Do you regularly use any drugs other than methamphetamine?
Yes

No

1 0. If yes, please indicate which drugs you currently use (circle all that apply):
A. Alcohol

E. Heroin

B. Marijuana

F. Hallucinogens (LSD, PCP, mushrooms, etc)

C. Cocaine

G. Prescription pills

D. Crack

H. Other (please specify) ________

1 1 . If you answered yes to question #9, do you consider Methamphetamine your primary
drug of choice (i.e. you use it much more regularly than the others)?
Yes

No

1 2. If you answered yes to question #9, please write in approximately how often you use
each in the blank:
A. Alcohol------

E. Heroin---------

B. Marijuana______

F. Hallucinogens______

C. Cocaine-------

G. Prescription pills_____

D. Crack--------

H. Other (please specify)___
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Appendix B
DEMOGRAPHIC INFORMATION SHEET
Age_____
Sex----Marital Status------Number of Members in Household-----Ethnic/Racial Background (choose the closest answer):
White/Caucasian---

Asian---

African American---

Pacific Islander---

Latino/Hispanic----

American Indian---

Other (please specify)___
Occupation_______________
Average Combined Household Income:
Under $15,000/yr____

$15,001-20,000/yr---

$20,001-30,000/yr___

$30,001-50,000/yr___

$50,001-75,000/yr___

Over $75,001/yr____

**FOR OFFICE USE ONLY (do not write below this line)**
Participant Identification #________
Accepted for Study______

1 28

Appendix C:
Informed Consent Statement

1 29

Appendix C
INFORMED CONSENT STATEMENT:
y
Ps chosocial Correlates of Methamphetamine Use
INTRODUCTION/PURPOSE
You have been invited to participate in a research study on methamphetamine (meth) use.
The goal of this study is to look for the effects that meth use has on behavior. In doing
so, we will help therapists to better assist people dealing with meth addiction. To do this,
we will have meth-users and non-users, tell us about their meth-use habits and other areas
of their lives. We will then look for problem areas associated with increased meth use.
INFORMATION ABOUT PARTICIPANTS' INVOLVEMENT IN THE STUDY
Your involvement in this study will require no more than one hour of your time. The
procedure for conducting this study is as follows:
I.
Obtain informed consent from participant
II.
Obtain demographic information from participant
III.
Complete the Multi-Problem Screening Inventory
IV.
Complete the Meth-Use Questionnaire
The questions asked in this study will relate to:
Meth-use; depression; self-esteem; partner problems; sexual problems; child,
mother, father, and family problems; stress; problems with friends, neighbors,
and co-workers; school problems; aggression; suicide; abuse; fear; guilt;
thoughts; memory; and alcohol and drug use.
RISKS
Risk to you in this study is considered minor and unlikely and falls into the category of
psychological risks:
Test anxiety/discomfort - you will be treated warmly, assured of your
confidentiality in giving responses, allowed to skip any question which creates
discomfort, and left alone while completing the surveys. In addition, if you are
currently seeing a therapist for any reason, you will be encouraged to discuss with
them any issues that may arise during your participation in this study.
BENEFITS
The main benefit to of this study is in learning more about the effects that meth use has
on human behavior. This information will be of use to therapists in understanding and
assisting their clients who are users. Non-meth users will benefit from this enhancement
of the treatment system in place to help their loved ones or others who may be users.

Participant's initials______
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CONFIDENTIALITY
All information that you give us will be kept strictly confidential. It will be viewed only
by those professionals directly involved in carrying out the research. Information which
could identi fy you will be kept separate from test results, in a secure, locked location. No
data will be transmitted electronically or saved on a computer' s hard drive. There will be
NO WAY to connect you to your responses. In addition, in contacting you about this
study, no answering machine or voice-mail messages will be left.
COMPENSATION
You will receive a $ 1 0 gift certificate when you finish filling out the surveys.
EMERGENCY MEDICAL TREATMENT
The authors of this research and the University of Tennessee are in no way liable for any
inj ury or other medical claims incurred during participation in this study. You hereby
waive all rights to compensation for medically related charges.
CONTACT INFORMATION
If you have any questions or comments about this study (or you experience negative
effects as a result of participating) you may contact the principal researcher Greg J.
Eisinger through UT's College of Social Work at (865) 974 - 648 1 , or by email at
geisinge@utk.edu. If you have questions about your rights as a participant feel free to
contact the UT' s Office of Research Compliance Officer at (865) 974 3466.
Participation
Your participation in this study is voluntary ; you may decide not to participate without
penalty. If you decide to participate, you may change your mind at anytime without
penalty and without loss of benefits to which you are otherwise entitled such as services
at Helen Ross McNabb. If you withdraw from the study before data collection is
completed your data will be returned to you or destroyed.

CONSENT
I have read the above information. I have received a copy of this form. I agree to
participate in this study.
Participant' s signature----------------- Date-----Researcher' s signature_________________ Date______
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Appendix D
Script For Briefing of Participants
Section 1

You are here because you have agreed to participate in a study on drug use. This
study is part of a University of Tennessee student's master' s thesis and may appear in
several professional publication s in the future. Your name will never be used in this
study, and NO OTHER INFORMATION WILL BE USED WHICH COULD
POSSIBLY CONNECT YOU TO YOUR RESPONSES. The con sent form that you just
signed is the only document that will ever bear your name, and it will never be attached
to, or refer to, your respon ses. In addition your respon ses will not even be viewed by
myself. Every precaution has been taken to ensure that no authorities, or anyone else, will
be able to connect you to your responses or take legal action against you as a result of
participating in this study. You may also withdraw from the study at any time without
penalty. You will receive a $ 10 gift certificate to McDonalds or Wal-Mart when you are
finished with your participation in about 45 minutes, and you will never be contacted
again .
Section 2

Now, I will ask you to give us some information about yourself. Please answer
each question with the response which most closely matches how you identify yourself.
We also ask that you DO NOT write your name anywhere on this form. When you are
finished, place the form into the manila envelope.
Section 3
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At this time, we will begin the testing portion of the study. You will be asked to
fill out
two different surveys. The first is an assessment of general functioning which will ask
you questions about 27 areas of your life. Please DO NOT WRITE YOUR NAME
anywhere on this sheet. This questionnaire is designed to obtain information about a wide
range of possible problem areas. Answer each item as carefully and accurately as you
can by placing a number beside each one as follows: 1 = none of the time; 2 = very
rarely; 3 = a little of the time; 4 = some of the time; 5 = a good part of the time; 6 = most
of the time; and 7 = all of the time. You can refer to this scale on each page of the survey
as well. You may discover that some of the items do not apply to you or your personal
situation. For any such item, please enter an "x" but do not leave the item blank. For
example, if the question asks about your children and you have none, please place an "x"
in the answer blank. When you begin to complete the items on this questionnaire you will
see that you can very easily make yourself look as good or bad as you wish. Please do not
do this. It is extremely important for you to provide that most accurate answers possible.
The most important thing for us is that you are made to feel at ease, and that you read
carefully, and respond honestly to, each question, as your responses will not be held
against you or made known to anyone outside of this study. However, you may also
choose not to answer any question which makes you uncomfortable. Any such question
you may simply leave blank. This first test will take about 30-40 minutes. When you are
finished, you may move on to the second survey. This 1 2-item questionnaire will ask you
about your habits in regards to methamphetamine use. Again, please feel free to respond
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honestly or not to answer a question if it makes you feel uncomfortable. Please DO NOT
WRITE YOUR NAME on this sheet either. This quick survey should only take about 51 0 minutes. When you are finished, please place the two surveys into the manila envelope
and seal it. You may bring the envelope back to the place where we met I will be waiting
to give you your $ 1 0 reward. You will not be contacted again after this. I will now leave
you alone to complete these surveys, so that I cannot see your responses. Do you have
any questions before we begin? Thank you very much for your participation in this
study, you may now begin.
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